

Ehret, G. B. et al. (2016) The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nature Genetics*, 48(10), pp. 1171-1184. (doi:<u>10.1038/ng.3667</u>) (PMID:<u>27618452</u>)

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

http://eprints.gla.ac.uk/123665/

Deposited on: 07 September 2016

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	The genetics of blood pressure regulation and its target organs from
16	association studies in 342,415 individuals

## 17 AUTHORS

Georg B. Ehret<sup>1,2\*</sup>, Teresa Ferreira<sup>3\*</sup>, Daniel I. Chasman<sup>4,5</sup>, Anne U. Jackson<sup>6,7</sup>, Ellen M. Schmidt<sup>8</sup>, Toby 18 Johnson<sup>9,10</sup>, Gudmar Thorleifsson<sup>11</sup>, Jian'an Luan<sup>12</sup>, Lousie A. Donnelly<sup>13</sup>, Stavroula Kanoni<sup>14</sup>, Ann-Kristin 19 Petersen<sup>15</sup>, Vasyl Pihur<sup>1</sup>, Rona J. Strawbridge<sup>16,17</sup>, Dmitry Shungin<sup>18,19,20</sup>, Maria F. Hughes<sup>21</sup>, Osorio 20 Meirelles<sup>22</sup>, Marika Kaakinen<sup>23</sup>, Nabila Bouatia-Naji<sup>24,25</sup>, Kati Kristiansson<sup>26,27</sup>, Sonia Shah<sup>28</sup>, Marcus E. 21 Kleber<sup>29</sup>, Xiuqing Guo<sup>30</sup>, Leo-Pekka Lyytikäinen<sup>31,32</sup>, Cristiano Fava<sup>33,34</sup>, Niclas Eriksson<sup>35</sup>, Ilja M. Nolte<sup>36</sup>, 22 Patrik K. Magnusson<sup>37</sup>, Elias L. Salfati<sup>38</sup>, Loukianos S. Rallidis<sup>39</sup>, Elizabeth Theusch<sup>40</sup>, Andrew J.P. Smith<sup>41</sup>, 23 Lasse Folkersen<sup>16</sup>, Kate Witkowska<sup>9,42</sup>, Tune H. Pers<sup>43,44,45,46,47</sup>, Roby Joehanes<sup>48</sup>, Stuart K. Kim<sup>49</sup>, Lazaros 24 Lataniotis<sup>14</sup>, Rick Jansen<sup>50</sup>, Andrew D. Johnson<sup>48,51</sup>, Helen Warren<sup>9,42</sup>, Young Jin Kim<sup>52</sup>, Wei Zhao<sup>53</sup>, Ying 25 Wu<sup>54</sup>, Bamidele O. Tayo<sup>55</sup>, Murielle Bochud<sup>56</sup>, CHARGE-EchoGen consortium<sup>57</sup>, CHARGE-HF 26 consortium<sup>57</sup>, Wellcome Trust Case Control Consortium<sup>57</sup>, Devin Absher<sup>58</sup>, Linda S. Adair<sup>59</sup>, Najaf Amin<sup>60</sup>, 27 Dan E. Arking<sup>1</sup>, Tomas Axelsson<sup>61</sup>, Damiano Baldassarre<sup>62,63</sup>, Beverley Balkau<sup>64</sup>, Stefania Bandinelli<sup>65</sup>, 28 Michael R. Barnes<sup>14,42</sup>, Inês Barroso<sup>66,67,68</sup>, Stephen Bevan<sup>69</sup>, Joshua C. Bis<sup>70</sup>, Gyda Bjornsdottir<sup>11</sup>, Michael 29 Boehnke<sup>6,7</sup>, Eric Boerwinkle<sup>71</sup>, Lori L. Bonnycastle<sup>72</sup>, Dorret I. Boomsma<sup>73</sup>, Stefan R. Bornstein<sup>74</sup>, Morris J. 30 Brown<sup>75</sup>, Michel Burnier<sup>76</sup>, Claudia P. Cabrera<sup>9,42</sup>, John C. Chambers<sup>77,78,79</sup>, I-Shou Chang<sup>80</sup>, Ching-Yu 31 Cheng<sup>81,82,83</sup>, Peter S. Chines<sup>72</sup>, Ren-Hua Chung<sup>84</sup>, Francis S. Collins<sup>72</sup>, John M. Connell<sup>85</sup>, Angela 32 Döring<sup>86,87</sup>, Jean Dallongeville<sup>88</sup>, John Danesh<sup>89,66,90</sup>, Ulf de Faire<sup>91</sup>, Graciela Delgado<sup>29</sup>, Anna F. 33 Dominiczak<sup>92</sup>, Alex S.F. Doney<sup>13</sup>, Fotios Drenos<sup>41</sup>, Sarah Edkins<sup>66</sup>, John D. Eicher<sup>48,51</sup>, Roberto Elosua<sup>93</sup>, 34 Stefan Enroth<sup>94,95</sup>, Jeanette Erdmann<sup>96,97</sup>, Per Eriksson<sup>16</sup>, Tonu Esko<sup>98,99,100</sup>, Evangelos Evangelou<sup>77,101</sup>, 35 Alun Evans<sup>21</sup>, Tove Fall<sup>102</sup>, Martin Farrall<sup>3,103</sup>, Janine F. Felix<sup>104</sup>, Jean Ferrières<sup>105</sup>, Luigi Ferrucci<sup>106</sup>, Myriam 36 Fornage<sup>107</sup>, Terrence Forrester<sup>108</sup>, Nora Franceschini<sup>109</sup>, Oscar H. Franco Duran<sup>104</sup>, Anders Franco-37 Cereceda<sup>110</sup>, Ross M. Fraser<sup>111,112</sup>, Santhi K. Ganesh<sup>113</sup>, He Gao<sup>77</sup>, Karl Gertow<sup>16,17</sup>, Francesco 38 Gianfagna<sup>114,115</sup>, Bruna Gigante<sup>91</sup>, Franco Giulianini<sup>4</sup>, Anuj Goel<sup>3,103</sup>, Alison H. Goodall<sup>116,117</sup>, Mark O. 39 Goodarzi<sup>118</sup>, Mathias Gorski<sup>119,120</sup>, Jürgen Gräßler<sup>121</sup>, Christopher Groves<sup>122</sup>, Vilmundur Gudnason<sup>123,124</sup>, 40 Ulf Gyllensten<sup>94,95</sup>, Göran Hallmans<sup>18</sup>, Anna-Liisa Hartikainen<sup>125,126</sup>, Maija Hassinen<sup>127</sup>, Aki S. Havulinna<sup>26</sup>, 41 Caroline Hayward<sup>128</sup>, Serge Hercberg<sup>129</sup>, Karl-Heinz Herzig<sup>130,131,132</sup>, Andrew A. Hicks<sup>133</sup>, Aroon D. 42 Hingorani<sup>28</sup>, Joel N. Hirschhorn<sup>43,44,45,134</sup>, Albert Hofman<sup>104,135</sup>, Jostein Holmen<sup>136</sup>, Oddgeir Lingaas 43 Holmen<sup>136,137</sup>, Jouke-Jan Hottenga<sup>73</sup>, Phil Howard<sup>41</sup>, Chao A. Hsiung<sup>84</sup>, Steven C. Hunt<sup>138,139</sup>, M. Arfan 44 Ikram<sup>104,140,141</sup>, Thomas Illig<sup>142,143,144</sup>, Carlos Iribarren<sup>145</sup>, Richard A. Jensen<sup>70,146</sup>, Mika Kähönen<sup>147</sup>, Hyun 45 Kang<sup>6,7</sup>, Sekar Kathiresan<sup>148,149,150,45,151</sup>, Brendan J. Keating<sup>152,153</sup>, Kay-Tee Khaw<sup>154</sup>, Yun Kyoung Kim<sup>52</sup>, Eric 46 Kim<sup>155</sup>, Mika Kivimaki<sup>28</sup>, Norman Klopp<sup>142,143</sup>, Genovefa Kolovou<sup>156</sup>, Pirjo Komulainen<sup>127</sup>, Jaspal S. 47 Kooner<sup>157,78,79</sup>, Gulum Kosova<sup>149,148,100</sup>, Ronald M. Krauss<sup>158</sup>, Diana Kuh<sup>159</sup>, Zoltan Kutalik<sup>160,161</sup>, Johanna 48

Kuusisto<sup>162</sup>, Kirsti Kvaløy<sup>136</sup>, Timo A Lakka<sup>163,127,164</sup>, Nanette R. Lee<sup>165,166</sup>, I-Te Lee<sup>167,168</sup>, Wen-Jane Lee<sup>169</sup>, 49 Daniel Levy<sup>48,170</sup>, Xiaohui Li<sup>30</sup>, Kae-Woei Liang<sup>171,172</sup>, Honghuang Lin<sup>173,48</sup>, Li Lin<sup>2</sup>, Jaana Lindström<sup>26</sup>, 50 Stéphane Lobbens<sup>174,175,176</sup>, Satu Männistö<sup>26</sup>, Gabriele Müller<sup>177</sup>, Martina Müller-Nurasyid<sup>15,178,179</sup>, 51 François Mach<sup>2</sup>, Hugh S. Markus<sup>180</sup>, Eirini Marouli<sup>14,181</sup>, Mark I. McCarthy<sup>122</sup>, Colin A. McKenzie<sup>108</sup>, Pierre 52 Meneton<sup>182</sup>, Cristina Menni<sup>183</sup>, Andres Metspalu<sup>98</sup>, Vladan Mijatovic<sup>184</sup>, Leena Moilanen<sup>185,186</sup>, May E. 53 Montasser<sup>187</sup>, Andrew D. Morris<sup>13</sup>, Alanna C. Morrison<sup>188</sup>, Antonella Mulas<sup>189</sup>, Ramaiah Nagaraja<sup>22</sup>, 54 Narisu Narisu<sup>72</sup>, Kjell Nikus<sup>190,191</sup>, Christopher J. O'Donnell<sup>192,48,151</sup>, Paul F. O'Reilly<sup>193</sup>, Ken K. Ong<sup>12</sup>, Fred 55 Paccaud<sup>56</sup>, Cameron D. Palmer<sup>194,195,45</sup>, Afshin Parsa<sup>187</sup>, Nancy L. Pedersen<sup>37</sup>, Brenda W. Penninx<sup>196,197,198</sup>, 56 Markus Perola<sup>26,27,98</sup>, Annette Peters<sup>87</sup>, Neil Poulter<sup>199</sup>, Peter P. Pramstaller<sup>133,200,201</sup>, Bruce M. 57 Psaty<sup>70,202,203,204</sup>, Thomas Quertermous<sup>38</sup>, Dabeeru C. Rao<sup>205</sup>, Asif Rasheed<sup>206</sup>, N William N.W.R. 58 Rayner<sup>122,3,66</sup>, Frida Renström<sup>19,207,18</sup>, Rainer Rettig<sup>208</sup>, Kenneth M. Rice<sup>209</sup>, Robert Roberts<sup>210,211</sup>, Lynda M. 59 Rose<sup>4</sup>, Jacques Rossouw<sup>212</sup>, Nilesh J. Samani<sup>116,213</sup>, Serena Sanna<sup>189</sup>, Jouko Saramies<sup>214</sup>, Heribert 60 Schunkert<sup>215,216,217,218</sup>, Sylvain Sebert<sup>219,131,164</sup>, Wayne H.-H. Sheu<sup>167,168,220</sup>, Young-Ah Shin<sup>52</sup>, Xueling 61 Sim<sup>6,7,221</sup>, Johannes H. Smit<sup>196</sup>, Albert V. Smith<sup>123,124</sup>, Maria X. Sosa<sup>1</sup>, Tim D. Spector<sup>183</sup>, Alena 62 Stančáková<sup>222</sup>, Alice Stanton<sup>223</sup>, Kathleen E. Stirrups<sup>14,224</sup>, Heather M. Stringham<sup>6,7</sup>, Johan Sundstrom<sup>61</sup>, 63 Amy J. Swift<sup>72</sup>, Ann-Christine Syvänen<sup>61</sup>, E-Shyong Tai<sup>225,82,221</sup>, Toshiko Tanaka<sup>106</sup>, Kirill V. Tarasov<sup>226</sup>, 64 Alexander Teumer<sup>227</sup>, Unnur Thorsteinsdottir<sup>11,124</sup>, Martin D. Tobin<sup>228</sup>, Elena Tremoli<sup>62,63</sup>, Andre G. 65 Uitterlinden<sup>104,229</sup>, Matti Uusitupa<sup>230,231</sup>, Ahmad Vaez<sup>36,232</sup>, Dhananjay Vaidya<sup>233</sup>, Cornelia M. van 66 Duijn<sup>104,234</sup>, Erik P.A. van Iperen<sup>235,236</sup>, Ramachandran S. Vasan<sup>48,237,238</sup>, Germaine C. Verwoert<sup>104</sup>, Jarmo 67 Virtamo<sup>26</sup>, Veronique Vitart<sup>128</sup>, Benjamin F. Voight<sup>45,239</sup>, Peter Vollenweider<sup>240</sup>, Aline Wagner<sup>241</sup>, Louise V. 68 Wain<sup>228</sup>, Nicholas J. Wareham<sup>12</sup>, Hugh Watkins<sup>3,103</sup>, Alan B. Weder<sup>242</sup>, Harm-Jan Westra<sup>243</sup>, Rainford 69 Wilks<sup>244</sup>, Tom Wilsgaard<sup>245,246</sup>, James F. Wilson<sup>111,128</sup>, Tien Y. Wong<sup>81,82,83</sup>, Tsun-Po Yang<sup>14,247</sup>, Jie Yao<sup>30</sup>, 70 Loic Yengo<sup>174,175,176</sup>, Weihua Zhang<sup>77,78</sup>, Jing Hua Zhao<sup>12</sup>, Xiaofeng Zhu<sup>248</sup>, Pascal Bovet<sup>249,56</sup>, Richard S. 71 Cooper<sup>55</sup>, Karen L. Mohlke<sup>54</sup>, Danish Saleheen<sup>250,206</sup>, Jong-Young Lee<sup>52</sup>, Paul Elliott<sup>77,251</sup>, Hinco J. 72 Gierman<sup>49,252</sup>, Cristen J. Willer<sup>8,253,254</sup>, Lude Franke<sup>255</sup>, G Kees Hovingh<sup>256</sup>, Kent D. Taylor<sup>30</sup>, George 73 Dedoussis<sup>181</sup>, Peter Sever<sup>199</sup>, Andrew Wong<sup>159</sup>, Lars Lind<sup>61</sup>, Themistocles L. Assimes<sup>38</sup>, Inger Njølstad<sup>245,246</sup>, 74 Peter EH. Schwarz<sup>74</sup>, Claudia Langenberg<sup>12</sup>, Harold Snieder<sup>36</sup>, Mark J. Caulfield<sup>9,42</sup>, Olle Melander<sup>33</sup>, 75 Markku Laakso<sup>162</sup>, Juha Saltevo<sup>257</sup>, Rainer Rauramaa<sup>127,164</sup>, Jaakko Tuomilehto<sup>26,258,259,260</sup>, Erik 76 Ingelsson<sup>102,3</sup>, Terho Lehtimäki<sup>31,32</sup>, Kristian Hveem<sup>136</sup>, Walter Palmas<sup>261</sup>, Winfried März<sup>262,263</sup>, Meena 77 Kumari<sup>28</sup>, Veikko Salomaa<sup>26</sup>, Yii-Der I. Chen<sup>30</sup>, Jerome I. Rotter<sup>30</sup>, Philippe Froguel<sup>174,175,176,23</sup>, Marjo-Riitta 78 Jarvelin<sup>219,131,264,251</sup>, Edward G. Lakatta<sup>226</sup>, Kari Kuulasmaa<sup>26</sup>, Paul W. Franks<sup>19,207,18</sup>, Anders Hamsten<sup>16,17</sup>, 79 H.-Erich Wichmann<sup>86,179,265</sup>, Colin N.A. Palmer<sup>13</sup>, Kari Stefansson<sup>11,124</sup>, Paul M Ridker<sup>4,5</sup>, Ruth J.F. 80

- 81 Loos<sup>12,266,267</sup>, Aravinda Chakravarti<sup>1</sup>, Panos Deloukas<sup>14,268</sup>, Andrew P. Morris<sup>269,3#</sup>, Christopher Newton-
- 82 Cheh<sup>148,149,45,100#</sup>, Patricia B. Munroe<sup>9,42#</sup>
- 83 <sup>\*</sup> These authors contributed equally to this work.
- <sup>#</sup> These authors jointly supervised this work.
- 85 Corresponding authors: Christopher Newton-Cheh (cnewtoncheh@mgh.harvard.edu) and Patricia B.
- 86 Munroe (p.b.munroe@qmul.ac.uk).
- 87

## 88 AUTHOR AFFILIATIONS

- 1. Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns
- 90 Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Cardiology, Department of Medicine, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1211
   Geneva 14, Switzerland
- 93 3. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
- 94 4. Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave. East,
- 95 Boston, MA 02215, USA
- 96 5. Harvard Medical School, Boston, MA 02115, USA
- 97 6. Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA
- 98 7. Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA
- 99 8. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 100 48109, USA
- 9. Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London,
   EC1M 6BQ, UK
- 103 10. GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
- 104 11. deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
- 105 12. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic
- 106 Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
- 107 13. Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee,
   108 DD1 9SY, UK
- 109 14. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen110 Mary University of London, London, UK
- 111 15. Institute of Genetic Epidemiology, Helmholtz Zentrum München, Neuherberg 85764, Germany
- 112 16. Cardiovascular Research Unit, Center for Molecular Medicine L8:03, Department of Medicine,
- 113 Karolinska Institutet, 171 76 Stockholm, Sweden
- 114 17. Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
- 115 18. Department of Public Health and Clinical Medicine, Umeå University, Sweden
- 116 19. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University
- 117 Hospital Malmö, SE-205 02 Malmö, Sweden
- 118 20. Department of Odontology, Umeå University, Sweden
- 21. Centre of Excellence for Public Health, Queens University Belfast, Grosvenor Road, Belfast BT126JP,UK
- 121 22. Laboratory of Genetics, Intramural Research Program, National Institute on Aging, National
- 122 Institutes of Health, Baltimore, Maryland 21224, USA
- 123 23. Department of Genomics of Common Disease, School of Public Health, Imperial College London,
- 124 Hammersmith Hospital, London, UK
- 125 24. INSERM UMR970, Paris Cardiovascular Research Center PARCC, 56 rue Leblanc, 75015 Paris, France
- 126 25. University Paris-Descartes, Sorbonne Paris Cité, 12 rue de l'Ecole de medicine, F-75006 Paris, France
- 127 26. National Institute for Health and Welfare, FI-00271 Helsinki, Finland
- 128 27. Institute for Molecular Medicine Finland FIMM, University of Helsinki, 00290 Helsinki, Finland
- 129 28. Genetic Epidemiology Group, Dept. Epidemiology and Public Health, UCL, London, WC1E 6BT, UK
- 130 29. Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-
- 131 Ufer 1-3, 68167 Mannheim, Germany
- 132 30. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research
- 133 Institute at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA
- 134 31. Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland

- 135 32. Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014,
- 136 Finland
- 137 33. University of Lund, Dept Internal Medicine, Malmo, SE 20502, Sweden
- 138 34. University of Verona, Dept of Internal Medicine, Verona, Italy 37134
- 139 35. Uppsala University, Uppsala Clinical Research Center, SE-75185 Uppsala, Sweden
- 140 36. Department of Epidemiology, University of Groningen, University Medical Center Groningen,
- 141 Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- 142 37. Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77
- 143 Stockholm, Sweden
- 144 38. Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
- 145 39. Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, 146 Athens. Greece
- 147 40. Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA
- 148 41. Department of Cardiovascular Genetics, Institute of Cardiovascular Sciences, University College 149 London, London WC1E 6JF, UK
- 150 42. NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London,
- 151 EC1M 6BQ, UK
- 152 43. Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA
- 153 44. Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA 02115, 154 USA
- 155 45. Program in Medical and Population Genetics, Broad Institute, 7 Cambridge Center, Cambridge, MA 156 02142, USA
- 157 46. Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic, Genetics,
- 158 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2100, Denmark
- 159 47. Department of Epidemiology Research, Statens Serum Institut, 2300, Copenhagen, Denmark
- 160 48. National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA
- 49. Dept. Dev. Bio. And Genetics, Stanford University Medical Center, Stanford, CA 94305, USA 161
- 162 50. Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
- 163 51. National Heart, Lung and Blood Institute, Cardiovascular Epidemiology and Human Genomics Branch, Bethesda, MD 20814, USA
- 164
- 165 52. Center for Genome Science, National Institute of Health, Osong Health Technology Administration 166 Complex, Chungcheongbuk-do, Republic of Korea
- 53. Division of Translational Medicine and Human Genetics, Department of Medicine, University of 167 168 Pennyslvania, USA
- 169 54. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA
- 170 55. Department of Preventive Medicine and Epidemiology, Loyola University Chicago Stritch School of
- 171 Medicine, Maywood, IL, 60153, USA
- 172 56. Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and
- 173 University of Lausanne, Route de la Corniche 10, 1010 Lausanne, Switzerland
- 174 57. A list of members and affiliations appears in the Supplementary Note
- 175 58. HudsonAlpha Institute for Biotechnology, Huntsville, AL 35086, USA
- 176 59. Department of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA
- 177 60. Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, 3015CN, The
- 178 Netherlands
- 179 61. Uppsala University, Department of Medical Sciences, SE-75185 Uppsala, Sweden
- 180 62. Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy
- 181 63. Centro Cardiologico Monzino, IRCCS, Milan, Italy

- 182 64. INSERM Centre for Research in Epidemiology and Population Health, U1018, Villejuif, France
- 183 University Paris-Sud, URMS 1018, Villejuif, France
- 184 65. Geriatric Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
- 185 66. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, CB10 1SA, Hinxton, UK
- 186 67. University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science
- 187 Box 289 Addenbrookes Hospital Cambridge CB2 OQQ, UK
- 188 68. NIHR Cambridge Biomedical Research Centre, Level 4, Institute of Metabolic Science Box 289
- 189 Addenbrookes Hospital Cambridge CB2 OQQ, UK
- 190 69. School of Life Science, University of Lincoln, Joseph Banks Laboratories, Lincoln LN6 7DL, UK
- 191 70. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle,
  192 WA 98101, USA
- 193 71. Human Genetics Center, School of Public Health, University of Texas Health Science Center at
- Houston, 1200 Pressler St., Suite 453E, Houston, TX 77030, USA
- 195 72. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute,
- 196 NIH, Bethesda, MD 20892, USA
- 197 73. Department of Biological Psychology, VU University, Amsterdam, The Netherlands
- 198 74. Dept of Medicine III, University of Dresden, Medical Faculty Carl Gustav Carus, Fetscherstrasse 74,
- 199 01307 Dresden, Germany
- 200 75. The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London,
- 201 London EC1M 6BQ, UK
- 76. Nephrology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 17, 1005Lausanne, Switzerland
- 204 77. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
- 205 Norfolk Place, London W2 1PG, UK
- 78. Department of Cardiology, Ealing Hospital NHS Trust, Uxbridge Road, Southall, Middlesex UB1 3EU,207 UK
- 208 79. Imperial College Healthcare NHS Trust, London, UK
- 209 80. National Institute of Cancer Research, National Health Research Institutes. 35 Keyan Rd., Zhunan
- 210 Town, Miaoli County 350, Taiwan
- 211 81. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore 168751, Singapore
- 212 82. Duke-NUS Graduate Medical School Singapore, Singapore 169857, Singapore
- 213 83. Department of Ophthalmology, National University of Singapore and National University Health
- 214 System, Singapore 119228
- 215 84. Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health
- 216 Research Institutes. 35 Keyan Rd., Zhunan Town, Miaoli County 350, Taiwan
- 217 85. University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
- 218 86. Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg 85764, Germany
- 219 87. Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg 85764, Germany
- 220 88. UMR744 Inserm-Lille2-Institut Pasteur Lille, France
- 221 89. Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
- 222 90. NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public
- 223 Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
- 91. Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
   Stockholm, Sweden
- 226 92. BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences,
- 227 University of Glasgow, 126 University Place, Glasgow, G12 8QT, UK
- 228 93. Cardiovascular Epidemiology and Genetics. IMIM (Institut Hospital del Mar d'Investigacions
- 229 Mèdiques), Barcelona, Spain

- 230 94. Department of Immunology, Genetics and Pathology, University of Uppsala, Box 815, Biomerical
- 231 center, 751 08 Uppsala, Sweden
- 232 95. Science for Life Laboratory, University of Uppsala, Box 815, Biomerical center, 751 08 Uppsala,
- 233 Sweden
- 234 96. Institut für Integrative und Experimentelle Genomik, Universiät zu Lübeck, RatzeburgerAllee 160,
- 235 23538 Lübeck, Germany
- 236 97. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Hamburg, Kiel, Lübeck,
- 237 Universität zu Lübeck, Lübeck, Germany
- 238 98. Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia
- 239 99. Divisions of Endocrinology/Children's Hospital, Boston, MA 02115, USA
- 240 100. Broad Institute of Harvard and MIT, Cambridge, MA 02139 USA
- 101. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110,
  Greece
- 243 102. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala
  244 University, Uppsala, Sweden
- 245 103. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford,
- 246 Oxford, OX3 9DU, UK
- 247 104. Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, P.O.Box 2040,
- 248 3000 CA Rotterdam, The Netherlands
- 249 105. Toulouse University School of Medicine, Rangueil University Hospital, INSERM UMR1027,
- 250 Toulouse, France
- 251 106. Translational Gerontology Branch, National Institute on Aging, Baltimore MD, USA
- 252 107. Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX, USA
- 253 108. Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West
- 254 Indies, Mona, Kingston 7, Jamaica
- 255 109. Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA
- 256 110. Cardiothoracic Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet,
- 257 171 76 Stockholm, Sweden
- 258 111. Institute for Population Health Sciences and Informatics, University of Edinburgh, Teviot Place,
- 259 Edinburgh, EH8 9AG, Scotland
- 260 112. Synpromics Ltd, 9 Bioquarter, Little France Road, Edinburgh, EH16 4UX, Scotland
- 261 113. University of Michigan Medical School, 7220 MSRB III, Ann Arbor MI 48109, USA
- 262 114. EPIMED Research Centre Epidemiology and Preventive Medicine, Department of Clinical and
- 263 Experimental Medicine, University of Insubria, Varese, Italy
- 264 115. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo
- 265 NEUROMED, 86077 Pozzilli, Italy
- 266 116. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3
  267 9QP, UK
- 268 117. National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit,
- 269 Glenfield Hospital, Leicester LE3 9QP, UK
- 118. Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA
  90048, USA
- 272 119. Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine,
- 273 University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
- 274 120. Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053
- 275 Regensburg, Germany
- 276 121. Department of Medicine III, Division Pathobiochemistry, Technische Universität Dresden, Dresden,
- 277 Germany

- 278 122. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK 279 123. Icelandic Heart Association, Kopavogur, Iceland 280 124. Faculty of Medicine, University of Iceland, Reykjavik, Iceland 281 125. Institute of Clinical Medicine/Obstetrics and Gynaecology, University of Oulu, Oulu, Finland 282 126. Medical Research Center, Oulu University Hospital, Oulu, Finland 283 127. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland 284 128. Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU 285 Scotland, UK 286 129. UREN, INSERM U557, INRA U1125, CNAM, SMBH, Sorbonne Paris Cité, Université Paris 13, 287 Bobigny, France 288 130. Institute of Biomedicine, University of Oulu, Medical Research Center Oulu and Oulu University 289 Hospital, Finland 290 131. Biocenter Oulu, P.O.Box 5000, Aapistie 5A, FI-90014 University of Oulu, Finland 291 132. Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, 292 Poland 293 133. Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, 39100, Italy -294 affiliated institute of the University of Lübeck, Germany 295 134. Department of Genetics, Harvard Medical School, Boston, 02115, USA 296 135. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA 297 136. HUNT Research Centre, Department of Public Health and General Practice, Norwegian University 298 of Science and Technology, 7600 Levanger, Norway 299 137. St. Olav Hospital, Trondheim University Hospital, Trondheim, Norway 300 138. Cardiovascular Genetics Division, University of Utah School of Medicine, Salt Lake City, Utah, USA 301 139. Department of Genetic Medicine, Weill Cornell Medical College Qatar, Doha, Qatar 302 140. Department of Radiology, Erasmus MC, The Netherlands 303 141. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, P.O.Box 2040, 3000 304 CA Rotterdam, The Netherlands 305 142. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg 85764, 306 Germany 307 143. Hannover Unified Biobank, Hannover Medical School, Hannover 30625, Germany 308 144. Hannover Medical School, Institute for Human Genetics, Carl-Neuberg-Strasse 1, 30625 Hanover, 309 Germany 310 145. Kaiser Permanente, Division of Research, Oakland, CA 94612, USA 311 146. Department of Medicine, University of Washington, Seattle, Washington 98101, USA 312 147. Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland 313 148. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA 314 149. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA 315 150. Department of Medicine, Harvard Medical School, Boston, MA, USA 316 151. Cardiology Division, Department of Medicine, Massachusetts General Hospital 317 152. Division of Transplantation, Department of Surgery, University of Pennsylvania, PA 19104 USA 318 153. Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA 319 154. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, 320 Cambridge CB2 2SR, UK 321 155. Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed 322 at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA 90502, USA 323 156. 1st Cardiology Department, Onassis Cardiac Surgery Center 356, Sygrou Ave, Athens, Greece 324 157. National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus,
  - 325 Ducane Road, London W12 ONN, UK

- 326 158. Department of Medicine, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA
- 327 159. MRC Unit for Lifelong Health and Ageing at UCL, London, WC1B 5JU, UK
- 328 160. Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
- 329 161. Swiss Institute of Bioinformatics, Lausanne, Switzerland
- 162. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, 70210Kuopio, Finland
- 332 163. Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Finland
- 164. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio,
   Finland
- 335 165. Office of Population Studies Foundation Inc., Talamban, Cebu City, 6000, Philippines
- 166. Department of Anthropology, Sociology, and History, University of San Carlos, Talamban, Cebu
   City, 6000, Philippines
- 167. Division of Endocrine and Metabolism, Department of Internal Medicine, Chichung Veterans
- 339 General Hospital, Taichung 40705, Taiwan
- 340 168. School of Medicine, National Yang-Ming University, Taipei, Taiwan
- 341 169. Department of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan
- 342 170. Population Sciences Branch, National Heart Lung, and Blood Institute, National Institutes of
- 343 Health, Bethesda, MD, USA
- 344 171. Cardiovascular Center, Taichung Veterans General Hospital, Taichung, 40705, Taiwan
- 345 172. Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei 112,
  346 Taiwan
- 347 173. Section of Computational Biomedicine, Department of Medicine, Boston University School of
- 348 Medicine, Boston, 02446 MA, USA
- 349 174. European Genomic Institute for Diabetes (EGID), FR 3508 Lille, France
- 175. Centre National de la Recherche Scientifique (CNRS) UMR 8199, Lille Pasteur Institute, 1 rue du
- 351 Prof Calmette, 59019 Lille Cedex, France
- 352 176. Lille 2 University, Lille, France
- 353 177. Center for Evidence-based Healthcare, University of Dresden, Medical Faculty Carl Gustav Carus,
- 354 Fetscherstrasse 74, 01307 Dresden, Germany
- 178. Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians University,

356 Munich, Germany

- 357 179. Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-
- 358 Maximilians-Universität, München 81377, Germany
- 180. Neurology Unit, University of Cambridge, R3, Box 83, Cambridge Biomedical Campus, Cambridge,
  Cb2 0QQ, UK
- 181. Department of Dietetics-Nutrition, Harokopio University, 70 El. Venizelou Str, Athens, Greece
- 362 182. INSERM U1142 LIMICS, UMR\_S 1142 Sorbonne Universités, UPMC Université Paris 06, Université
- 363 Paris 13, Paris, France
- 183. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
- 184. Department of Life and Reproduction Sciences, University of Verona, Strada le Grazie 8, 37134
  Verona, Italy
- 367 185. Department of Medicine, Kuopio University Hospital, Kuopio, Finland
- 368 186. Unit of General Practice, Oulu University Hospital, Oulu, Finland
- 369 187. Department of Medicine, Program for Personalized and Genomic Medicine, University of
- 370 Maryland, School of Medicine, Baltimore, Maryland 21201, USA
- 188. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public
- Health, University of Texas Health Science Center at Houston, 1200 Pressler St., Suite 453E, Houston, TX
- 373 77030, USA

- 189. Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella
  Universitaria di Monseratto, Monserrato, Cagliari 09042, Italy
- 190. Department of Cardiology, School of Medicine, University of Tampere, Tampere 33014, Finland
- 191. School of Medicine, University of Tampere, Tampere 33014, Finland
- 192. National Heart, Lung and Blood Institute, Division of Intramural Research, Bethesda, MD, USA
- 193. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
- 380 194. Divisions of Endocrinology, Children's Hospital Boston, Massachusetts 02115, USA
- 381 195. Genetics and Program in Genomics, Children's Hospital Boston, Massachusetts 02115, USA
- 382 196. Department of Psychiatry, EMGO Institute, Neuroscience Campus, VU University Medical Centre,
- 383 Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
- 384 197. Department of Psychiatry, University of Groningen, University Medical Center Groningen,
- 385 Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- 198. Department of Psychiatry, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The
   Netherlands
- 388 199. International Centre for Circulatory Health, Imperial College London, W2 1PG, UK
- 389 200. Department of Neurology, General Central Hospital, Bolzano, 39100, Italy
- 390 201. Department of Neurology, University of Lübeck, Lübeck, Germany
- 391 202. Department of Epidemiology, University of Washington, Seattle, WA, USA
- 392 203. Department of Health Services, University of Washington, Seattle, WA
- 393 204. Group Health Research Institute, Group Health Cooperative, Seattle, WA
- 205. Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, 63110, USA
- 395 206. Center for Non-Communicable Diseases, Karachi, Pakistan
- 396 207. Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
- 208. Institute of Physiology, University Medicine Greifswald, Greifswald, Germany
- 398 209. Department of Biostatistics, University of Washington, Seattle, WA, USA
- 399 210. University of Ottawa Heart Institute, Cardiovascular Research Methods Centre Ontario, Canada
- 400 211. Ruddy Canadian Cardiovascular Genetics Centre, Ontario, Canada
- 401 212. National Heart, Lung, and Blood Institute, 6701 Rockledge Ave., Bethesda, MD 20892, USA
- 402 213. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester
   403 LE3 9QP, UK
- 404 214. South Karelia Central Hospital, Lappeenranta, Finland
- 405 215. Deutsches Herzzentrum München, Germany
- 406 216. Technische Universität München, Germany
- 407 217. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), München, Germany
- 408 218. Munich Heart Alliance, Germany
- 409 219. Center For Life-course Health Research, P.O.Box 5000, FI-90014 University of Oulu, Finland
- 410 220. College of Medicine, National Defense Medical Center, Taipei, Taiwan
- 411 221. Saw Swee Hock School of Public Health, National University of Singapore and National University
- 412 Health System, Singapore 117597
- 413 222. University of Eastern Finland and Kuopio University Hospital, 70210 Kuopio, Finland
- 414 223. Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4,
- 415 Ireland
- 416 224. Department of Haematology, University of Cambridge, Cambridge, UK
- 417 225. Department of Medicine, National University of Singapore and National University Health System,
- 418 Singapore 119228, Singapore
- 419 226. Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging,
- 420 National Institutes of Health, Baltimore, Maryland, 21224, USA
- 421 227. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany

- 422 228. Department of Health Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK 423 229. Department of internal medicine, Erasmus MC, Rotterdam, 3000CA, The Netherlands 424 230. Department of Public Health and Clinical Nutrition, University of Eastern Finland, Finland 425 231. Research Unit, Kuopio University Hospital, Kuopio, Finland 426 232. Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of 427 Medical Sciences, Isfahan, Iran 428 233. Johns Hopkins Medical Institutions, 1830 East Monument St., Baltimore, MD 21287, USA 429 234. Centre of Medical Systems Biology (CMSB 1-2), NGI Erasmus Medical Center, Rotterdam, The 430 Netherlands 431 235. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, 432 Amsterdam, The Netherlands 433 236. Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The 434 Netherlands 435 237. Section of Preventive medicine, Department of Medicine, Boston University School of Medicine, 436 Boston, 02446 MA, USA 437 238. Cardiology, Department of Medicine, Boston University School of Medicine, Boston, 02446 MA, 438 USA 439 239. Department of Pharmacology, University of Pennsylvania Perelman School of Medicine, 440 Philadelphia, Pennsylvania, USA 441 240. Department of Internal medicine, University Hospital Lausanne, Lausanne, Switzerland 442 241. Department of Epidemiology and Public Health, EA3430, University of Strasbourg, Strasbourg, 443 France 444 242. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan 445 Medical School, Ann Arbor, MI, USA 446 243. University Medical Center Groningen, University of Groningen, Groningen, 9700RB, The 447 Netherlands 448 244. Epidemiology Research Unit, Tropical Medicine Research Institute, University of the West Indies, 449 Mona, Kingston 7, Jamaica 245. Department of Community Medicine, Faculty of Health Sciences, University of Troms<sup>-</sup>, Troms<sup>-</sup>, 450 451 Norway 452 246. Department of Clinical Medicine, Faculty of Health Sciences, University of Troms<sup>-</sup>, Troms<sup>-</sup>, Norway 453 247. MRC Cancer Unit, University of Cambridge, Cambridge, UK 454 248. Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve 455 University, Cleveland, OH, 44106, USA 249. Ministry of Health, Victoria, Republic of Seychelles 456 457 250. Department of Biostatistics and Epidemiology, University of Pennsylvania, USA 458 251. MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, 459 Norfolk Place, London W2 1PG, UK 460 252. Enterprise Informatics, Illumina Inc., Santa Clara CA, 95050, USA 461 253. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann 462 Arbor, MI 48109, USA 463 254. Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA 464 255. Department of Genetics, University of Groningen, University Medical Centre Groningen, 465 Groningen, 9711, The Netherlands 466 256. Dept Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands 467 257. Department of Medicine, Central Finland Health Care District, Jyväskylä, Finland 468 258. Dasman Diabetes Institute, Dasman, 15462 Kuwait
  - 469 259. Saudi Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia

- 470 260. Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria
- 471 261. Department of Medicine, Columbia University, 622 West 168th St., New York, NY 10032, USA
- 472 262. Synlab Academy, Synlab Services GmbH, P5, 7, 68161 Mannheim, Germany
- 263. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036
  474 Graz, Austria
- 475 264. Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O.Box 20, FI-90220 Oulu, 90029
- 476 OYS, Finland
- 477 265. Grosshadern, Klinikum, München 81377, Germany
- 478 266. The Charles Bronfman Institute for Personalized Medicine, The Icahn School of Medicine at Mount
- 479 Sinai, New York, NY 10029, USA
- 480 267. Mindich Child health Development Institute, The Icahn School of Medicine at Mount Sinai, New
  481 York, NY 10029, USA
- 482 268. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-
- 483 HD), King Abdulaziz University, Jeddah 21589, Saudi Arabia
- 484 269. Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, UK

## 486 ABSTRACT

487 To dissect the genetic architecture of blood pressure and assess effects on target-organ damage, 488 we analyzed 128,272 SNPs from targeted and genome-wide arrays in 201,529 individuals of European 489 ancestry and genotypes from an additional 140,886 individuals were used for validation. We identified 490 66 blood pressure loci, of which 17 were novel and 15 harbored multiple distinct association signals. 491 The 66 index SNPs were enriched for *cis*-regulatory elements, particularly in vascular endothelial cells, 492 consistent with a primary role in blood pressure control through modulation of vascular tone across 493 multiple tissues. The 66 index SNPs combined in a risk score showed comparable effects in 64,421 494 individuals of non-European descent. The 66-SNP blood pressure risk score was significantly associated 495 with target-organ damage in multiple tissues, with minor effects in the kidney. Our findings expand 496 current knowledge of blood pressure pathways and highlight tissues beyond the classic renal system in 497 blood pressure regulation.

## 498 INTRODUCTION

499 There are considerable physiological, clinical and genetic data that point to the kidney as the 500 major regulator of blood pressure (BP) and to renal damage as a consequence of long-term BP elevation. 501 However, alternative hypotheses, such as increasing systemic vascular resistance, are also serious 502 contenders to explain the rise of BP with increasing age, but with limited genetic support. The genetic 503 basis of elevated blood pressure or hypertension (HTN) involves many loci that have been identified using large-scale analyses of candidate genes<sup>1,2</sup>, linkage studies, and genome-wide association studies 504 (GWAS)<sup>3-12</sup>. The genes underlying BP regulation can help resolve many of the open questions regarding 505 BP (patho-) physiology. While ~40-50% of BP variability is heritable  $^{13,14}$ , the genetic variation identified 506 to date explains only  $\sim 2\%^{1-12}$ . 507

The Cardio-MetaboChip is a custom genotyping microarray designed to facilitate cost-effective follow-up of nominal associations for metabolic and cardiovascular traits, including BP. This array comprises 196,725 variants, including ~5,000 SNPs with nominal (P < 0.016) evidence of BP association in our previous GWAS meta-analysis<sup>5</sup>. Furthermore, the array includes several dense scaffolds for fine mapping of selected loci spanning, on average, genomic regions of 350 kilobases<sup>5,16</sup>, of which 24 include genome-wide significant BP association in the current study<sup>5,16</sup>.

## 514 **RESULTS**

## 515 Novel genetic loci associated with systolic and diastolic BP

We performed meta-analyses of association summary statistics from a total of 201,529
individuals of European (EUR) ancestry from 74 studies: (i) 109,096 individuals from 46 studies
genotyped on Cardio-MetaboChip; and (ii) 92,433 individuals from 28 studies with imputed genotype
data from genome-wide genotyping at variants included on the Cardio-MetaboChip. Twenty-four of the
28 studies with genome-wide genotyping data had contributed to previous analyses (Supplementary
Tables 1-3)<sup>5,7</sup>.

BP was measured using standardized protocols in all studies<sup>5,17</sup> (**Supplementary Table 1, Online methods**). Association statistics for systolic and diastolic BP (SBP and DBP) in models adjusting for age, age<sup>2</sup>, sex, and body mass index (BMI), were obtained for each study separately, with study-specific genomic control applied to correct for possible population structure. Fixed-effects meta-analysis proceeded in 4 stages, separately for the following SNP associations: Stage 1, using results based on 46 studies using Cardio-MetaboChip genotypes of 109,096 participants; Stage 2, using additional results based on imputed genotypes from genome-wide genotyping arrays in 4 previously unpublished studies;

529 Stage 3 using imputed genotypes from genome-wide genotyping arrays in 24 previously published studies<sup>5</sup>; and Stage 4, the joint meta-analysis of Stages 1-3 including a total of 201,529 independent 530 531 individuals (Supplementary Figure 1, Supplementary Tables 2-3, Supplementary Note). To account for 532 population structure between studies in Stages 1-3 of our meta-analysis, genomic control correction was 533 applied to meta-analysis results from each of these stages in an approach aggregating summary statistics from GWAS and Cardio-MetaboChip studies<sup>18,19</sup>. 534

After stage 4, 67 loci attained genome-wide significance ( $P < 5 \times 10^{-8}$ ), 18 of which were not 535 536 previously reported in the literature (Supplementary Table 4). Quantile-quantile plots of the stage 4 537 meta-analysis showed an excess of small P values, with an elevated genomic control lambda estimate 538 that was persistent, albeit attenuated, after excluding all 66 loci (Supplementary Figure 2). This 539 observation is compatible with either residual uncorrected population stratification or the presence of a 540 large number of variants that are truly associated with BP but fail to achieve genome-wide significance in the current meta-analysis. The Cardio-MetaboChip array's inclusion of SNPs from a prior BP GWAS<sup>5</sup> 541 542 does not appear to be the sole explanation, as we did not observe a significant decrease of the excess of 543 small P values after exclusion of all SNPs that were included on the Cardio-MetaboChip based on 544 nominal BP association (Supplementary Figures 3 and 4). Since the quantile-quantile plots continued to 545 show deviation from the null expectation, we sought additional validation for 18 variants attaining genome-wide significance, but without prior support in the literature, in up to 140,886 individuals of 546 European ancestry from UK Biobank<sup>20</sup>. For these SNPs, we performed a stage 5 meta-analysis combining 547 548 the association summary statistics from stage 4 and UK Biobank, in a total of up to 342,415 individuals

549 (Supplementary Table 5).

550 Upon stage 5 meta-analysis, 17 of 18 variants retained genome-wide significance for the primary 551 trait (SBP or DBP result with the lower P value). The one variant that was not genome-wide significant had a borderline P value of  $4.49 \times 10^{-8}$  at stage 4. These findings are consistent with appropriate 552 553 calibration of the association test statistics at stage 4 such that observing one failure among 18 validation tests is consistent with the use of a threshold ( $P < 5 \times 10^{-8}$ ) designed to have a 1 in 20 chance 554 of a result as or more extreme solely due to chance. In total, 66 loci attained genome-wide significance: 555 13 loci for SBP only, 12 loci for DBP only, and 41 loci for both traits. Of these, 17 BP loci were novel, 556 while 49 were previously reported at genome-wide significance (Table 1 and Figure 1). 557

Compared with previously reported BP variants<sup>5,7,21</sup>, the average absolute effect size of the 558 559 newly discovered variants is smaller, with comparable minor allele frequency (MAF), presumably owing 560 to the increased power of a larger sample size (Table 2). As expected from the high correlation between

SBP and DBP effects, the observed directions of effects for the two traits were generally concordant
(Supplementary Figure 5), and the absolute effect sizes were inversely correlated with MAF (Table 1
and Supplementary Figure 6). The 66 BP SNPs explained 3.46% and 3.36% of SBP and DBP variance,
respectively, a modest increase from 2.95% and 2.78% for SBP and DBP, respectively, for the 49
previously reported SNPs (Supplementary Note). The low percent variance explained is consistent with
estimates that large numbers of common variants with weak effects at a large number of loci influence
BP<sup>5</sup>.

## 568 Signal refinement at the 66 BP loci

569 To identify distinct signals of association at the 66 BP loci and the variants most likely to be 570 causal for each, we started with an approximate conditional analysis using a model selection procedure implemented in the GCTA-COJO package<sup>22,23</sup> as well as a detailed literature review of all published BP 571 572 association studies. GCTA-COJO analysis was performed using the association summary statistics for SBP 573 and DBP from the Stage 4 EUR ancestry meta-analyses, with the linkage disequilibrium (LD) between 574 variants estimated on the basis of Cardio-MetaboChip genotype data from 7,006 individuals of EUR ancestry from the GoDARTS cohort<sup>24</sup>. More than one distinct BP association signal was identified at 13 575 loci at  $P < 5 \times 10^{-8}$  (Supplementary Table 6, Supplementary Figures 7, and Supplementary Note). At six 576 577 loci, the distinct signals were identified for both SBP and DBP analyzed separately; these trait-specific associations were represented by the same or highly correlated ( $r^2 > 0.8$ ) SNPs at 5 of the 6 loci 578 579 (Supplementary Tables 7 and 8). We repeated GCTA-COJO analyses using the same summary 580 association results, but with a different reference sample for LD estimates (WTCCC1-T2D/58BC, N = 581 2,947, Supplementary Note) and observed minimal differences arising from minor fluctuations in the 582 association P value in the joint regression models (Supplementary Tables 7 and 8). LD-based 583 comparisons of published association signals at established BP loci, and the current study's findings 584 suggested that at 10 loci, the signals identified by the single-SNP and the GCTA-COJO analyses were 585 distinct from those reported in the literature (Supplementary Table 9).

We then performed multivariable regression modeling in a single large cohort (Women's
Genome Health Study, WGHS, N = 23,047) with simultaneous adjustment for both 1) all combinations of
putative index SNPs for each distinct signal from the GCTA-COJO conditional analyses, and 2) all index
SNPs for all potential distinct signals identified by our literature review (Supplementary Table 9,
Supplementary Note). Although WGHS is very large as a single study, power is reduced in a single
sample compared to that in the overall meta-analysis (23k vs. 342k individuals) and consequently the

failure to reach significance does not represent non-replication for individual SNPs. The WGHS analysis
supported two distinct association signals at eight of 13 loci identified in the GCTA-COJO analysis, but
could not provide support for the remaining five (Supplementary Table 10). The joint SNP modeling in
WGHS additionally supported two distinct signals of association at three other loci (*GUCY1A3-GUCY1B3*, *SYNPO2L* and *TBX5-TBX3*), at which the SNP identified in the current study is distinct from that
previously reported in the literature<sup>5,11</sup>.

598 We sought to refine the localization of likely functional variants at loci with high-density 599 coverage on the Cardio-MetaboChip. We followed a Bayesian approach to define, for each signal, 600 credible sets of variants that have 99% probability of containing or tagging the causal variant 601 (Supplementary Note). To improve the resolution of the method, the analyses were restricted to 24 602 regions selected to fine map (FM) genetic associations, and that included at least one SNP reaching genome-wide significance in the current meta-analyses (Supplementary Table 11). Twenty-one of the 603 604 Cardio-MetaboChip FM regions were BP loci in the original design, with three of the newly discovered 605 BP loci in FM regions that were originally selected for other non-BP traits. We observed that the 99% 606 credible SNP sets at five BP loci spanned <20kb. The greatest refinement was observed at the SLC39A8 607 locus for SBP and DBP, and at the ZC3HC1 and PLCE1 loci for DBP, where the 99% credible sets included 608 only the index variants (Supplementary Table 12). Although SNPs in credible sets were primarily non-609 coding, they included one synonymous and seven non-synonymous variants that attained high posterior 610 probability of driving seven distinct association signals at six BP loci (Supplementary Table 12). Of 611 these, three variants alone account for more than 95% of the posterior probability of driving the 612 association signal observed at each of three loci (Supplementary Table 12 and 13). Despite reduced 613 statistical power, the analyses restricted to the samples with Cardio-MetaboChip genotypes only 614 (N = 109,096) identified the majority of SNPs identified in the GWAS+Cardio-MetaboChip data 615 (Supplementary Table 12). The full list of SNPs in the 99% credible sets are listed in Supplementary 616 Table 13.

## 617 What do the BP variants do?

Index SNPs or their proxies (r<sup>2</sup> > 0.8) altered amino acid sequence at 11 of 66 BP loci (**Table 1**). Thus, the majority of BP-association signals are likely driven by non-coding variants hypothesized to regulate expression of some nearby gene in *cis*. To characterize their effects, we first sought SNPs associated with gene expression (eSNPs) from a range of available expression data which included hypertension target end organs and cells of the circulatory system (heart tissue, kidney tissue, brain

623 tissue, aortic endothelial cells, blood vessels) and other tissue/cell types (CD4<sup>+</sup> macrophages, monocytes 624 lymphoblastoid cell lines, skin tissue, fat tissue, and liver tissue). Fourteen BP-associated SNPs at the 625 MTHFR-NPPB, MDM4, ULK4, CYP1A1-ULK3, ADM, FURIN-FES, FIGN, and PSMD5 loci were eSNPs across 626 different tissues (Supplementary Table 14). Of these 14 eSNPs, three were also predicted to alter the amino acid sequence at the MTHFR-NPPB, MAP4 and ULK4 loci, providing two potential mechanisms to 627 628 explore in functional studies. Second, we used gene expression levels measured in whole blood in two different samples each including >5,000 individuals of EUR descent. We tested whether the lead BP SNP 629 630 was associated with expression of any transcript in *cis* (<1Mb from the lead SNP at each locus) at a false 631 discovery rate (FDR) of < 0.05, accounting for all possible *cis*-transcript association tests genome-wide. 632 It is likely that we did not genotype the causal genetic variant underlying each BP association signal; a 633 nearby SNP-transcript association, due to LD, may therefore reflect an independent genetic effect on expression that is unrelated to the BP effect. Consequently, we assumed that the lead BP SNP and the 634 most significant eSNP for a given transcript should be highly correlated ( $r^2 > 0.7$ ). Furthermore, we 635 636 assumed that the significance of the transcript association with the lead BP SNP should be substantially 637 reduced in a conditional model adjusting for the best eSNP for a given transcript. Eighteen SNPs at 15 638 loci were associated with 22 different transcripts, with a total of 23 independent SNP-transcript 639 associations (three SNPs were associated with two transcripts each, Supplementary Table 15, 640 **Supplementary Note**). The genes expressed in a BP SNP allele-specific manner are clearly high-priority 641 candidates to mediate the BP association. In whole blood, these genes included obvious biological 642 candidates such as GUCY1A3, encoding the alpha subunit of the soluble guanylate cyclase protein, and ADM, encoding adrenomedullin, both of which are known to induce vasodilation<sup>25,26</sup>. There was some 643 644 overlap of eSNPs between the whole blood and other tissue datasets at the MTHFR-NPPB, MDM4, 645 PSMD5, ULK4 and CYP1A1-ULK3 loci, illustrating additional potentially causal genes for further study. 646 An alternative method for understanding the effect on BP of non-coding variants is to determine 647 whether they fall within DNasel hypersensitivity sites (DHSs). We performed two analyses to investigate whether BP SNPs or their LD proxies ( $r^2 > 0.8$ ) were enriched in DHSs in a cell-type-specific manner 648 (Supplementary Note). First, we used Epigenomics Roadmap and ENCODE DHS data from 123 adult cell 649 lines or tissues<sup>27-29</sup> to estimate the fold increase in the proportion of BP SNPs mapping to DHSs 650 651 compared to SNPs associated at genome-wide significance with non-BP phenotypes from the NHGRI GWAS catalog<sup>30</sup>. We observed that 7 out of the 10 cell types with the greatest relative enrichment of BP 652 653 SNPs mapping to DHSs were from blood vessels (vascular or micro-vascular endothelial cell-lines or cells) and 11 of the 12 endothelial cells were among the top quarter most enriched among the 123 cell types 654

(Figure 2 and Supplementary Table 16). In a second analysis of an expanded set of tissues and cell lines, in which cell types were grouped into tissues (Supplementary Table 17), BP-associated SNP enrichment in DHSs in blood vessels was again observed ( $P = 1.2 \times 10^{-9}$ ), as well as in heart samples ( $P = 5.3 \times 10^{-8}$ ; Supplementary Table 18).

We next tested whether there was enrichment of BP SNPs in H3K4me3<sup>31</sup> sites, a methylation mark associated with both promoter and enhancer DNA. We observed significant enrichment in a range of cell types including CD34 primary cells, adult kidney cells, and muscle satellite cultured cells (Supplementary Table 19). Enrichment of BP SNPs in predicted strong and weak enhancer states and in active promoters<sup>32</sup> in a range of cell types was also observed (Supplementary Table 20, Supplementary Figure 8).

We used Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA)<sup>33</sup> to attempt 665 to identify pathways over-represented in the BP association results. No gene sets meeting experiment-666 wide significance for enrichment for BP association were identified by MAGENTA after correction for 667 668 multiple testing, although some attained nominal significance (Supplementary Table 21, Supplementary **Note**). We also adapted the DEPICT<sup>34</sup> pathway analysis tool (Data-driven Expression Prioritized 669 Integration for Complex Traits) to identify assembled gene-sets that are enriched for genes near 670 671 associated variants, and to assess whether genes from associated loci were highly expressed in 672 particular tissues or cell types. Using the extended BP locus list based on genome-wide significant loci 673 from this analysis and previously published SNPs that may not have reached genome-wide significance 674 in the current analysis (**Supplementary Table 9**), we identified five significant (FDR  $\leq$  5%) gene sets: abnormal cardiovascular system physiology, G Alpha 1213 signaling events, embryonic growth 675 676 retardation, prolonged QT interval, and abnormal vitelline vasculature morphology. We also found that suggestive SBP and DBP associations ( $P < 1 \times 10^{-5}$ ) were enriched for reconstituted gene-sets at DBP loci 677 678 (mainly related to developmental pathways), but not at SBP loci (Supplementary Table 22, 679 Supplementary Note). In a final analysis, we assessed Cardio-MetaboChip SNPs at the fine-mapping loci using formaldehyde-assisted isolation of regulatory elements (FAIRE-gen) in lymphoblastoid cell lines<sup>35</sup>. 680 Our results provided support for two SNPs, one of which SNP (rs7961796 at the TBX5-TBX3 locus) was 681 located in a regulatory site. Although the other SNP (rs3184504 at the SH2B3 locus) is a non-682 synonymous variant, there was also a regulatory site indicated by DNaseI and H3K4me1 signatures at 683 the locus, making the SNP a potential regulatory variant (Supplementary Table 23)<sup>36</sup>. Both SNPs were 684 685 included in the list of 99% credible SNPs at each locus.

## 686 Asian- and African ancestry BP SNP association

687 We tested the 66 lead SNPs at the established and novel loci for association with BP in up to 688 20,875 individuals of South Asian (SAS) ancestry (PROMIS and RACE studies), 9,637 individuals of East 689 Asian (EAS) ancestry (HEXA, HALST, CLHNS, DRAGON, and TUDR studies), and 33,909 individuals of 690 African (AFR) ancestry (COGENT-BP consortium, Jupiter, SPT, Seychelles, GXE, and TANDEM studies). As 691 expected, the effect allele frequencies are very similar across studies of the same ethnicity, but markedly different across different ancestry groups (Supplementary Figure 9). Many associations of 692 693 individual SNPs failed to reach P < 0.05 for the BP trait with the lower P value (Supplementary Table 24), 694 which could potentially be due to the much lower statistical power at the sample sizes available, 695 different patterns of LD at each locus across ancestries, variability in allele frequency, or true lack of 696 association in individuals of a given non-European ancestry. The low statistical power for the great 697 majority of SNPs tested is visible considering SNP-by-SNP power calculations using European ancestry effect sizes (Supplementary Table 24). However, concordant directions of allelic effects for both SBP 698 699 and DBP were observed for 45/66 SNPs in SAS, 36/60 SNPs in EAS, and 42/66 SNPs in AFR samples: the 700 strongest concordance with SAS may not be surprising because South Asians are more closely related to 701 Europeans than are East Asians or Africans. Moreover, strong correlation of effect sizes was observed 702 between EUR samples with SAS, EAS, or AFR samples (r = 0.55, 0.60, and 0.48, respectively). A 66-SNP 703 SBP or DBP risk score were significant predictors of SBP and DBP in all samples. A 1 mm Hg higher SBP or 704 DBP risk score in EUR samples was associated with a 0.58/0.50 mm Hg higher SBP/DBP in SAS samples  $(SBP P = 1.5 \times 10^{-19}, DBP P = 3.2 \times 10^{-15}), 0.49/0.50 \text{ mm Hg higher SBP/DBP in EAS samples (SBP)}$ 705  $P = 1.9 \times 10^{-10}$ , DBP  $P = 1.3 \times 10^{-7}$ ), and 0.51/0.47 mm Hg higher SBP/DBP in AFR samples (SBP) 706  $P = 2.2 \times 10^{-21}$ , DBP  $P = 6.5 \times 10^{-19}$ ). The attenuation of the genetic risk score estimates in non-European 707 708 ancestries is presumably due to inclusion of a subset of variants that lack association in the non-709 European or admixed samples.

710 We subsequently performed a trans-ethnic meta-analysis of the 66 SNPs in all 64,421 samples across the three non-European ancestries. After correcting for 66 tests, 12/66 SNPs were significantly 711 associated with either SBP or DBP ( $P < 7.6 \times 10^{-4}$ ), with a correlation of EUR and non-EUR effect 712 713 estimates of 0.77 for SBP and 0.67 for DBP; the European-ancestry SBP or DBP risk score was associated with 0.53/0.48 mm Hg higher BP per predicted mm Hg SBP/DBP respectively (SBP  $P < 6.6 \times 10^{-48}$ , DBP 714  $P < 1.3 \times 10^{-38}$ ). For 7 of the 12 significant SNPs, no association has previously been reported in genome-715 716 wide studies of non-European ancestry. Some heterogeneity of effects was observed between European and non-European effect estimates (Supplementary Table 24). Taken together, these findings 717

- 718 suggest that, in aggregate, BP loci identified using data from individuals of EUR ancestry are also
- 719 predictive of BP in non-EUR samples, but larger non-European sample sizes will be needed to establish
- 720 precisely which individual SNPs are associated in a given ethnic group.

## 721 Impact on hypertensive target organ damage

722 Long-term elevated BP causes target organ damage, especially in the heart, kidney, brain, large 723 blood vessels, and the retinal vessels<sup>37</sup>. Consequently, the genetic effect of the 66 SBP and DBP SNPs on end-organ outcomes can be directly tested using the risk score, although some outcomes lacked results 724 725 for a small number of SNPs. Interestingly, BP risk scores significantly predicted (Supplementary Note) 726 coronary artery disease risk, left ventricular mass and wall thickness, stroke, urinary albumin/creatinine 727 ratio, carotid intima-medial thickness and central retinal artery caliber, but not heart failure or other 728 kidney phenotypes, after accounting for the number of outcomes examined (Table 3). Because outlier 729 effects can affect risk scores, we repeated the risk score analysis removing iteratively SNPs that 730 contributed to statistical heterogeneity (SNP-trait effects relative to SNP-BP effects). Heterogeneity was 731 defined based on a multiple testing adjusted significance threshold for Cochran's Q test of homogeneity 732 of effects (Supplementary Note). The risk score analyses restricted to the subset of SNPs showing no 733 heterogeneity of effect revealed essentially identical results, with the exception that urinary 734 albumin/creatinine ratio was no longer significant. The per-SNP results are provided in **Supplementary** 735 Table 25 and Supplementary Figures 10. Because large-scale GWAS of non-BP cardiovascular risk 736 factors are available, we examined the BP risk scores as predictors of other cardiovascular risk factors: 737 LDL-cholesterol, HDL-cholesterol, triglycerides, type 2 diabetes, BMI, and height. We observed nominal 738 (P < 0.05) associations of the BP risk scores with risk factors, although mostly in the opposite direction to 739 the risk factor-CVD association (Supplementary Table 26). The failure to demonstrate an effect of BP 740 risk scores on heart failure may reflect limited power from a modest sample size, but the lack of 741 significant effects on renal measures suggests that the epidemiologic relationship of higher BP and 742 worse renal function may not reflect direct consequences of BP elevation.

## 743 **DISCUSSION**

The study reported here is the largest to date to investigate the genomics of BP in multiple continental ancestries. Our results highlight four major features of inter-individual variation in BP: (1) we identified 66 (17 novel) genome-wide significant loci for SBP and DBP by targeted genotyping in up to 342,415 individuals of European ancestry that cumulatively explain ~3.5% of the trait; (2) the variants were enriched for *cis*-regulatory elements, particularly in vascular endothelial cells; (3) the variants had

broadly comparable BP effects in South Asians, East Asian and Africans, albeit in smaller sample sizes;
and, (4) a 66 SNP risk-score predicted target organ damage in the heart, cerebral vessels, carotid artery
and the eye with little evidence for an effect in kidneys. Overall, there was no enrichment of a single
genetic pathway in our data; rather, our results are consistent with the effects of BP arising from
multiple tissues and organs.

754 Genetic and molecular analyses of Mendelian syndromes of hypertension and hypotension point 755 largely to a renal origin, involving multiple rare deleterious mutations in proteins that regulate saltwater balance<sup>38</sup>. This is strong support for Guyton's hypothesis that the regulation of sodium excretion 756 757 by the kidney and its effects on extracellular volume are a prime pathway determining intra-arterial pressure<sup>39</sup>. However, our genetic data from unselected individuals in the general community argues 758 759 against a single dominant renal effect. The 66 SNPs we identified are not chance effects, but have a 760 global distribution and impact on BP that are consistent as measured by their effects across the many 761 studies meta-analyzed. That they are polymorphic across all continental ancestries argues for their 762 origin and functional effects prior to human continental differentiation.

763 However several of the 17 novel loci contain strong positional biological candidates, these are 764 described in greater detail in Supplementary Table 27 and the Supplementary Note. The single most 765 common feature we identified was the enrichment of regulatory elements for gene expression in 766 vascular endothelial cells. The broad distribution of these cells across both large and small vessels and 767 across all tissues and organs suggest that functional variation in these cells affects endothelial 768 permeability or vascular smooth muscle cell contractility via multiple pathways. These hypotheses will 769 need to be rigorously tested in appropriate models, to assess the contribution of these pathways to BP 770 control, and these pathways could also be targets for systemic anti-hypertensive therapy as they are for 771 the pulmonary circulation<sup>42</sup>.

In summary, these genetic observations may contribute to an improved understanding of BPbiology and a re-evaluation of the pathways considered relevant for therapeutic BP control.

## 774 SUPPLEMENTARY NOTE

575 Supplementary Note is available in the online version of the paper.

## 776 SUMMARY STATISTICS

Full summary statistics (*P* values) are in the online version of the paper (file "ICBPCMfinalMeta.csv.zip").

## 778 URLs

- 779 http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwDnase for enrichment
- 780 analyses. Accessed 3/13/2013.
- 781 http://www.genome.gov/gwastudies for enrichment analyses. Accessed 3/13/2013.
- 782 http://genome.ucsc.edu/ENCODE/cellTypes.html for enrichment analyses. Accessed 3/13/2013.

## 783 ACKNOWLEDGEMENTS

- 784 We thank all the study participants of this study for their contributions. Detailed acknowledgment of
- funding sources is provided in the **Supplementary Note.**

## 786 AUTHOR CONTRIBUTIONS

## 787 Analysis group

- 788 Design of secondary analyses: G.B.E., T.Ferreira, T.J., A.P.M., P.B.M., C.N.-C. Computation of secondary
- 789 analyses: G.B.E., T.Ferreira, T.J., A.P.M., P.B.M., C.N.-C. Paper writing: A.C., G.B.E., T.Ferreira, T.J., A.P.M.,
- 790 P.B.M., C.N.-C. Study management: P.B.M., C.N.-C.

## 791 Cardio-MetaboChip or new GWAS

- 792 WGHS: Study phenotyping: P.M.R., D.I.C., L.M.R. Genotyping or analysis: P.M.R., D.I.C., L.M.R.,
- 793 F.Giulianini Study PI: P.M.R.
- 794 JUPITER: Study phenotyping: P.M.R., D.I.C., L.M.R. Genotyping or analysis: D.I.C., L.M.R., F.Giulianini
- 795 Study PI: P.M.R., D.I.C.
- 796 deCODE: Study phenotyping: G.B. Genotyping or analysis: G.T. Study PI: K.S., U.T.
- 797 GoDARTS: Study phenotyping: C.N.A.P., L.A.D., A.D.M., A.S.F.D. Genotyping or analysis: C.N.A.P., L.A.D.,
- 798 A.D.M., M.I.M., C.G., N.W.W.R.R. Study PI: C.N.A.P., A.D.M.
- 799 KORA F3/F4: Study phenotyping: A.D., H.Schunkert, J.E. Genotyping or analysis: A.-K.P., M.M.-N., N.K.,
- 800 T.I. Study PI: H.-E.W., A.Peters
- 801 GLACIER: Study phenotyping: F.R., G.H. Genotyping or analysis: P.W.F., D.Shungin, I.B., S.Edkins, F.R. 802 Study PI: P.W.F.
- 803 B58C: Genotyping or analysis: S.Kanoni, K.E.S., Wellcome Trust Case Control Consortium, E.M.,
- 804 T.Ferreira, T.J. Study PI: P.D.
- 805 MORGAM: Study phenotyping: K.Kuulasmaa, F.Gianfagna, A.Wagner, J.Dallongeville Genotyping or
- 806 analysis: M.F.H., F.Gianfagna Study PI: J.V., J.F., A.E.
- 807 SardiNIA: Study phenotyping: E.G.L. Genotyping or analysis: E.G.L., O.Meirelles, S.Sanna, R.N., A.Mulas,
- 808 K.V.T.

- 809 NFBC1986: Study phenotyping: M.R.J., S.Sebert, K.H.H., A.L.H. Genotyping or analysis: M.Kaakinen,
- 810 A.L.H. Study PI: M.R.J.
- 811 DESIR: Genotyping or analysis: N.B.-N., L.Y., S.L. Study PI: P.F., N.B.-N., B.B.
- 812 DILGOM: Study phenotyping: S.M. Genotyping or analysis: K.Kristiansson, M.P., A.S.H. Study PI: V.S.
- 813 IMPROVE: Study phenotyping: D.B. Genotyping or analysis: R.J.S., K.G. Study PI: A.Hamsten, E.Tremoli
- 814 HyperGEN: Study phenotyping: S.C.H., D.C.R. Genotyping or analysis: A.C., V.P., G.B.E. Study PI: S.C.H.
- 815 FENLAND (MetaboChip): Study phenotyping: R.J.F.L., J.a.L., N.J.W., K.K.O. Genotyping or analysis:
- 816 R.J.F.L., J.a.L., N.J.W., K.K.O. Study PI: N.J.W.
- 817 Whitehall II: Study phenotyping: M.Kumari Genotyping or analysis: M.Kumari, S.Shah, C.L. Study PI:
- 818 A.Hingorani, M.Kivimaki
- 819 LURIC: Genotyping or analysis: M.E.K., G.Delgado Study PI: W.M.
- 820 MESA: Study phenotyping: W.P. Genotyping or analysis: W.P., X.G., J.Y., V.D., K.D.T., J.I.R., Y.-D.C. Study 821 PI: W.P.
- 822 HUNT2: Study phenotyping: K.Kvaløy, J.H., O.L.H. Genotyping or analysis: A.U.J. Study PI: K.H.
- 823 FINCAVAS: Genotyping or analysis: T.L., L.-P.L., K.N., M.Kähönen Study PI: T.L., M.Kähönen
- 824 GenNet: Study phenotyping: R.S.C., A.B.W. Genotyping or analysis: A.C., V.P., M.X.S., D.E.A., G.B.E.
- 825 Study PI: A.C., R.S.C., A.B.W.
- 826 SCARFSHEEP: Study phenotyping: B.G. Genotyping or analysis: R.J.S. Study PI: A.Hamsten, U.d.F.
- 827 DPS: Study phenotyping: J.L. Genotyping or analysis: A.U.J., P.S.C. Study PI: J.T., M.U.
- 828 DR's EXTRA: Study phenotyping: P.K. Genotyping or analysis: A.U.J., M.H. Study PI: R.Rauramaa, T.A.L.
- 829 FIN-D2D 2007: Genotyping or analysis: A.U.J., L.L.B. Study PI: J.Saltevo, L.M.
- 830 METSIM: Study phenotyping: H.M.S. Genotyping or analysis: A.U.J., A.Stančáková Study PI: M.L., J.K.
- 831 MDC-CVA: Study phenotyping: O.Melander Genotyping or analysis: O.Melander, C.F. Study PI:
- 832 O.Melander
- BRIGHT: Study phenotyping: A.F.D., M.J.B., N.J.S., J.M.C. Genotyping or analysis: T.J., P.B.M. Study PI:
  M.J.C., A.F.D., M.J.B., N.J.S., J.M.C., P.B.M.
- 835 NESDA: Study phenotyping: J.H.S. Genotyping or analysis: H.Snieder, I.M.N. Study PI: B.W.P.
- 836 EPIC (MetaboChip): Study phenotyping: R.J.F.L., J.a.L., N.J.W. Genotyping or analysis: J.a.L., N.J.W.
- 837 Study PI: N.J.W., K.-T.K.
- 838 ELY: Study phenotyping: C.L., J.a.L., N.J.W. Genotyping or analysis: C.L., J.a.L., N.J.W. Study PI: N.J.W.
- 839 DIAGEN: Study phenotyping: J.G., G.M. Genotyping or analysis: A.U.J., G.M. Study PI: P.E.S., S.R.B.
- 840 GOSH: Study phenotyping: P.K.M., N.L.P. Genotyping or analysis: E.I., P.K.M., N.L.P., T.Fall Study PI: E.I.
- 841 Tromsø: Study phenotyping: T.W. Genotyping or analysis: A.U.J., A.J.S., N. Study PI: I.N.
- ADVANCE: Study phenotyping: T.L.A., C.I. Genotyping or analysis: T.L.A., E.L.S., T.Q. Study PI: T.L.A.,
  T.Q., C.I.
- 844 ULSAM: Study phenotyping: E.I., J.Sundstrom Genotyping or analysis: E.I., N.E., J.Sundstrom, A.-C.S. 845 Study PI: J.Sundstrom
- 846 PIVUS: Study phenotyping: L.Lind, J.Sundstrom Genotyping or analysis: L.Lind, N.E., J.Sundstrom, T.A.
- 847 Study PI: L.Lind, J.Sundstrom
- 848 MRC NSHD: Study phenotyping: D.K. Genotyping or analysis: A.Wong, J.a.L., D.K., K.K.O. Study PI: D.K.
- ASCOT: Study phenotyping: A.Stanton, N.P. Genotyping or analysis: T.J., M.J.C., P.B.M. Study PI: P.S., M.J.C.
- 851 THISEAS: Genotyping or analysis: L.S.R., S.Kanoni, E.M., G.Kolovou Study PI: G.Dedoussis, P.D.
- PARC: Study phenotyping: R.M.K. Genotyping or analysis: K.D.T., E.Theusch, J.I.R., X.L., M.O.G., Y.D.I.C.
  Study PI: R.M.K.
- 854 AMC-PAS: Genotyping or analysis: G.K.H., P.D. Study PI: G.K.H.
- 855 CARDIOGENICS: Genotyping or analysis: S.Kanoni, A.H.G. Study PI: P.D., A.H.G., J.E., N.J.S., H.Schunkert
- 856 Secondary analyses

- 857 Allele-specific FAIRE: Design of secondary analysis: A.J.P.S. Computation of secondary analysis: A.J.P.S.,
- 858 F.D., P.H.
- 859 ASAP eQTL: Design of secondary analysis: A.F.C. Computation of secondary analysis: L.Folkersen,
- 860 P.Eriksson
- 861 CARDIOGENICS eQTL: Computation of secondary analysis: L.Lataniotis
- 862 CM design: P.B.M., C.N.-C., T.J., B.F.V.
- 863 Comprehensive literature review: Design of secondary analysis: P.B.M. Computation of secondary
- analysis: K.W., P.B.M.
- 865 DEPICT: Design of secondary analysis: L.Franke, T.H.P., J.N.H. Computation of secondary analysis: T.H.P.
- 866 DHS and methylation analysis by tissue:Design of secondary analysis: C.J.W. Computation of secondary 867 analysis: E.M.S.
- 868 DHS and methylation by cell-line: Design of secondary analysis: D.I.C. Computation of secondary 869 analysis: D.I.C., F.Giulianini
- 870 FHS eSNP: Design of secondary analysis: R.Joehanes Computation of secondary analysis: R.Joehanes
- 871 ICBP SC: C.N.-C., M.J.C., P.B.M., A.C., K.M.R., P.-O'R., W.P., D.L., M.D.T., B.M.P., A.D.J., P.Elliott, C.M.v.D.,
- 872 D.I.C., A.V.S., M.Bochud, L.V.W., H.Snieder, G.B.E.
- 873 Kidney eQTL: Computation of secondary analysis: H.J.G., S.K.K.
- 874 MAGENTA: Design of secondary analysis: D.I.C. Computation of secondary analysis: D.I.C.
- 875 Miscellaneous: Computation of secondary analysis: H.Warren
- 876 MuTHER eQTL: Design of secondary analysis: P.D. Computation of secondary analysis: L.Lataniotis, T.-877 P.Y.
- 878 NESDA eQTL: Design of secondary analysis: R.Jansen Computation of secondary analysis: R.Jansen, A.V.
- NTR eQTL: Design of secondary analysis: R.Jansen Computation of secondary analysis: R.Jansen, J.-J.H.
  Study PI: D.I.B.
- 881 eQTL, EGCUT: Design of secondary analysis: A.Metspalu Computation of secondary analysis: T.E.,
- 882 A.Metspalu
- 883 eQTL, Groningen:Design of secondary analysis: L.Franke Computation of secondary analysis: H.J.W., 884 L.Franke
- Public eSNP and methylation: Design of secondary analysis: A.D.J., J.D.E. Computation of secondary
  analysis: A.D.J., J.D.E.
- 887 PubMed search: Design of secondary analysis: G.B.E. Computation of secondary analysis: G.B.E., L.Lin
- 888 WGHS conditional: Design of secondary analysis: D.I.C. Computation of secondary analysis: D.I.C.,
- 889 F.Giulianini, L.M.R.

## 890 Lookup of Cardio-MetaboChip variants

- 891 HEXA: Genotyping or analysis: Y.J.K., Y.K.K., Y.-A.S. Study PI: J.-Y.L.
- 892 RACe: Study phenotyping: D.Saleheen, W.Zhao, A.R., A.R. Genotyping or analysis: W.Zhao, A.R., A.R.
- 893 Study PI: D.Saleheen
- HALST: Study phenotyping: C.A.H. Genotyping or analysis: J.I.R., Y.-D.C., C.A.H., R.-H.C., I.-S.C. Study PI:
  C.A.H.
- CLHNS: Study phenotyping: N.R.L., L.S.A. Genotyping or analysis: Y.W., N.R.L., L.S.A. Study PI: K.L.M.,L.S.A.
- 898 GxE/Spanish Town: Study phenotyping: B.O.T., C.A.M., R.W. Genotyping or analysis: C.D.P. Study PI:
- 899 R.S.C., C.A.M., R.W., T.Forrester, J.N.H.
- 900 DRAGON: Study phenotyping: W.-J.L., W.H.-H.S., K.-W.L., I-Te Lee Genotyping or analysis: J.I.R., Y.-D.C.,
- 901 E.K., D.A., K.D.T., X.G. Study PI: W.H.-H.S.
- 902 SEY: Study phenotyping: P.B. Genotyping or analysis: M.Bochud, G.B.E., F.M. Study PI: P.B., M.Bochud,
- 903 M.Burnier, F.P.

- 904 TUDR: Study phenotyping: W.H.-H.S., I-Te Lee, W.-J.L. Genotyping or analysis: J.I.R., Y.-D.C., E.K., K.D.T.,
- 905 X.G. Study PI: W.H.-H.S.
- 906 TANDEM: Study phenotyping: P.B., M.Bochud Genotyping or analysis: G.B.E., F.M. Study PI: P.B.,
- 907 M.Bochud, M.Burnier, F.P.

## 908 Imputed genotypes

- 909 FHS: Study phenotyping: D.L. Genotyping or analysis: D.L. Study PI: D.L.
- 910 ARIC: Study phenotyping: E.B. Genotyping or analysis: G.B.E., E.B., A.C.M., A.C., S.K.G. Study PI: E.B.,
- 911 A.C.
- 912 RS: Genotyping or analysis: G.C.V., A.G.U. Study PI: A.Hofman, A.G.U., O.H.F.D.
- 913 CoLaus: Study phenotyping: P.V. Genotyping or analysis: Z.K. Study PI: P.V.
- 914 NFBC1966: Study phenotyping: M.R.J. Genotyping or analysis: P.O.R. Study PI: M.R.J.
- 915 SHIP: Study phenotyping: R.Rettig Genotyping or analysis: A.T.
- 916 CHS: Study phenotyping: B.M.P. Genotyping or analysis: K.M.R. Study PI: B.M.P.
- 917 EPIC (GWAS): Study phenotyping: N.J.W., R.J.F.L., J.a.L. Genotyping or analysis: N.J.W., J.H.Z., J.a.L.
- 918 Study PI: N.J.W., K.-T.K.
- 919 SU.VI.MAX: Study phenotyping: S.H. Genotyping or analysis: S.H., P.M. Study PI: P.M.
- 920 Amish: Genotyping or analysis: M.E.M. Study PI: A.Parsa
- 921 FENLAND (GWAS): Study phenotyping: N.J.W., J.a.L., R.J.F.L., K.K.O. Genotyping or analysis: N.J.W.,
- 922 J.a.L., R.J.F.L., K.K.O. Study PI: N.J.W.
- 923 DGI: Study phenotyping: C.N.C. Genotyping or analysis: C.N.C., G.Kosova Study PI: C.N.C.
- 924 ERF (EUROSPAN): Genotyping or analysis: N.A. Study PI: C.M.v.D.
- 925 MIGEN: Study phenotyping: S.Kathiresan, R.E. Genotyping or analysis: S.Kathiresan, R.E. Design of
- 926 secondary analysis: S.Kathiresan, R.E.
- 927 MICROS: Study phenotyping: P.P.P. Genotyping or analysis: A.A.H. Study PI: A.A.H., P.P.P.
- 928 FUSION: Genotyping or analysis: A.U.J. Study PI: M.Boehnke, F.S.C., K.L.M., J.Saramies
- 929 TwinsUK: Genotyping or analysis: C.M. Study PI: T.D.S.
- 930 PROCARDIS: Genotyping or analysis: M.Farrall, A.G. Study PI: M.Farrall
- 931 BLSA: Study phenotyping: L.Ferrucci Genotyping or analysis: T.T. Study PI: L.Ferrucci
- 932 ORCADES: Study phenotyping: J.F.W. Study PI: J.F.W.
- 933 Croatia-Vis: Genotyping or analysis: V.V., C.H. Study PI: V.V., C.H.
- 934 NSPHS: Genotyping or analysis: S.Enroth Study PI: U.G.
- 935 InCHIANTI: Genotyping or analysis: T.T. Study PI: S.Bandinelli
- 936 AGES Reykjavik: Study phenotyping: V.G. Genotyping or analysis: A.V.S. Study PI: V.G.
- 937 Lookup
- 938 CARDIoGRAMplusC4D: Genotyping or analysis: P.D. Study PI: J.Danesh, H.Schunkert, T.L.A., J.E.,
- 939 S.Kathiresan, R.Roberts, N.J.S., P.D.
- 940 CHARGE cIMT: Genotyping or analysis: C.O'D., J.C.B.
- 941 CHARGE EYE: Genotyping or analysis: T.Y.W., X.S., R.A.J. Study PI: T.Y.W.
- 942 CHARGE-HF consortium: Study phenotyping: R.S.V., J.F.F. Genotyping or analysis: H.L., J.F.F. Study PI:
- 943 R.S.V.
- 944 CKDGen: Genotyping or analysis: M.G., V.M.
- 945 COGENT: Study phenotyping: N.F., J.R. Genotyping or analysis: N.F., X.Z., B.J.K., B.O.T., J.R.
- 946 EchoGen consortium: Study phenotyping: R.S.V., J.F.F. Genotyping or analysis: H.L., J.F.F. Study PI:
- 947 R.S.V.
- 948 KidneyGen Consortium: Study phenotyping: J.C.C., J.S.K., P.Elliott Genotyping or analysis: W.Zhang,
- 949 J.C.C., J.S.K. Study PI: J.C.C., J.S.K.
- 950 MetaStroke: Genotyping or analysis: S.Bevan, H.S.M.
- 951 NeuroCHARGE: Genotyping or analysis: M.Fornage, M.A.I. Study PI: M.A.I.

- 952 PROMIS: Study phenotyping: D.Saleheen, W.Zhao, J.Danesh Genotyping or analysis: W.Zhao Study PI:
- 953 D.Saleheen
- 954 SEED: Study phenotyping: T.Y.W., C.-Y.C. Genotyping or analysis: E.-S.T, C.-Y.C., C.-Y.C. Study PI: C.-Y.C., 955 T.Y.W.
- 956 UK Biobank: BP group leaders: Mark Caulfield, P.Elliott Genotyping or analysis: M.R.B., H.Warren,
- 957 Claudia Cabrera, Evangelos Evangelou, He Gao.

## 958 COMPETING FINANCIAL INTERESTS

959 The authors declare competing financial interests (see corresponding section in the Supplementary

- 960 Note).
- 961

## 962 **REFERENCES**

963 1. Johnson, T. et al. Blood Pressure Loci Identified with a Gene-Centric Array. The American Journal 964 of Human Genetics 89, 1-13 (2011). 965 2. Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating 966 natriuretic peptides and blood pressure. Nature genetics 41, 348-53 (2009). 967 3. Franceschini, N. et al. Genome-wide association analysis of blood-pressure traits in African-968 ancestry individuals reveals common associated genes in African and non-African populations. 969 Am J Hum Genet 93, 545-54 (2013). 970 4. Ganesh, S.K. et al. Effects of long-term averaging of quantitative blood pressure traits on the 971 detection of genetic associations. Am J Hum Genet 95, 49-65 (2014). 972 5. Ehret, G.B. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular 973 disease risk. Nature 478, 103-109 (2011). 974 6. Wain, L.V. et al. Genome-wide association study identifies six new loci influencing pulse 975 pressure and mean arterial pressure. Nat Genet 43, 1005-11 (2011). 976 7. Newton-Cheh, C. et al. Genome-wide association study identifies eight loci associated with 977 blood pressure. Nat Genet 41, 666-76 (2009). 978 8. Simino, J. et al. Gene-age interactions in blood pressure regulation: a large-scale investigation 979 with the CHARGE, Global BPgen, and ICBP Consortia. Am J Hum Genet 95, 24-38 (2014). 980 9. Tragante, V. et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry 981 identifies multiple blood-pressure-related loci. Am J Hum Genet 94, 349-60 (2014). 982 10. Wang, Y. et al. From the Cover: Whole-genome association study identifies STK39 as a 983 hypertension susceptibility gene. Proc Natl Acad Sci U S A 106, 226-31 (2009). 984 11. Kato, N. et al. Meta-analysis of genome-wide association studies identifies common variants 985 associated with blood pressure variation in east Asians. *Nature genetics* **43**, 531-8 (2011). 986 12. Padmanabhan, S. et al. Genome-wide association study of blood pressure extremes identifies 987 variant near UMOD associated with hypertension. *PLoS genetics* 6, e1001177 (2010). 988 Miall, W.E. & Oldham, P.D. The hereditary factor in arterial blood-pressure. Br Med J 1, 75-80 13. 989 (1963). 990 Levy, D. et al. Framingham Heart Study 100K Project: genome-wide associations for blood 14. 991 pressure and arterial stiffness. BMC Med Genet 8 Suppl 1, S3 (2007). 992 Teslovich, T.M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. 15. 993 Nature 466, 707-13 (2010). 994 Voight, B.F. et al. The metabochip, a custom genotyping array for genetic studies of metabolic, 16. 995 cardiovascular, and anthropometric traits. PLoS Genet 8, e1002793 (2012). 996 17. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. & Burton, P.R. Adjusting for treatment effects in studies 997 of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med 24, 2911-998 35 (2005). 999 18. Locke, A.E. et al. Genetic studies of body mass index yield new insights for obesity biology. 1000 Nature 518, 197-206 (2015). 1001 Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. 19. 1002 Nature 518, 187-96 (2015). 1003 20. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range 1004 of complex diseases of middle and old age. PLoS Med 12, e1001779 (2015). 1005 Levy, D. et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 21. 1006 41, 677-87 (2009). 1007 22. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies 1008 additional variants influencing complex traits. Nat Genet 44, 369-75, S1-3 (2012).

1009 1010	23.	Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. <i>Am J Hum Genet</i> <b>88</b> , 76-82 (2011).
1010	24	Kimber, C.H. <i>et al.</i> TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both
	24.	
1012		diabetes susceptibility and control of glucose levels. <i>Diabetologia</i> <b>50</b> , 1186-91 (2007).
1013	25.	Erdmann, J. <i>et al.</i> Dysfunctional nitric oxide signalling increases risk of myocardial infarction.
1014		Nature <b>504</b> , 432-6 (2013).
1015	26.	Hirata, Y. et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney.
1016		Hypertension <b>25</b> , 790-5 (1995).
1017	27.	Epigenomics Roadmap et al. Integrative analysis of 111 reference human epigenomes. Nature
1018		<b>518</b> , 317-30 (2015).
1019	28.	Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. Nature
1020		<b>489</b> , 57-74 (2012).
1021	29.	Maurano, M.T. et al. Systematic localization of common disease-associated variation in
1022		regulatory DNA. Science <b>337</b> , 1190-5 (2012).
1023	30.	Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic
1024		Acids Res <b>42</b> , D1001-6 (2014).
1025	31.	Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait
1026		variants. Nat Genet <b>45</b> , 124-30 (2013).
1027	32.	Ernst, J. <i>et al.</i> Mapping and analysis of chromatin state dynamics in nine human cell types.
1028	-	Nature <b>473</b> , 43-9 (2011).
1029	33.	Segre, A.V. <i>et al.</i> Common inherited variation in mitochondrial genes is not enriched for
1030		associations with type 2 diabetes or related glycemic traits. <i>PLoS Genet</i> 6(2010).
1031	34.	Pers, T.H. <i>et al.</i> Biological interpretation of genome-wide association studies using predicted
1032	5.11	gene functions. <i>Nat Commun</i> <b>6</b> , 5890 (2015).
1033	35.	Giresi, P.G., Kim, J., McDaniell, R.M., Iyer, V.R. & Lieb, J.D. FAIRE (Formaldehyde-Assisted
1035	55.	Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin.
1035		Genome Res <b>17</b> , 877-85 (2007).
1035	36.	Stergachis, A.B. <i>et al.</i> Conservation of trans-acting circuitry during mammalian regulatory
1030	50.	evolution. <i>Nature</i> <b>515</b> , 365-70 (2014).
1037	37.	Mancia, G. <i>et al.</i> 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task
1038	57.	Force for the Management of Arterial Hypertension of the European Society of Hypertension
1039		(ESH) and of the European Society of Cardiology (ESC). <i>Eur Heart J</i> <b>34</b> , 2159-219 (2013).
1040	20	
	38.	Lifton, R., Somlo, S., Giebisch, G. & Seldin, D. <i>Genetic Diseases of the Kidney</i> , (Academic Press, 2000)
1042	20	2009).
1043	39.	Coffman, T.M. & Crowley, S.D. Kidney in hypertension: guyton redux. <i>Hypertension</i> <b>51</b> , 811-6
1044		(2008).
1045	40.	Kim, C.H. <i>et al.</i> Mutations in the dopamine beta-hydroxylase gene are associated with human
1046		norepinephrine deficiency. <i>American journal of medical genetics</i> <b>108</b> , 140-7 (2002).
1047	41.	Deinum, J. <i>et al.</i> DBH gene variants that cause low plasma dopamine beta hydroxylase with or
1048		without a severe orthostatic syndrome. <i>Journal of medical genetics</i> <b>41</b> , e38 (2004).
1049	42.	Ghofrani, H.A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J
1050		Med <b>369</b> , 330-40 (2013).
1051		

## 1053 FIGURE LEGENDS

## 1054 Figure 1. Manhattan plots for SBP and DBP from the stage 4 Cardio-MetaboChip-wide meta-analysis.

1055 *P* values (expressed as  $-\log_{10}P$ ) are plotted by physical genomic position labeled by chromosome. SNPs in 1056 new loci (3.5MB window around the index SNP), identified in this study, are labeled in dark red (SBP) or 1057 dark blue (DBP); SNPs in previously known loci are labeled in orange (SBP) or light blue (DBP). The locus 1058 names are indicated. The grey crosses indicate genomic positions at which the y-axis was truncated 1059 (SNPs with  $P < 10^{-15}$ ).

Figure 2. Enrichment of DNAse hypersensitive sites among BP loci in different cell-types. Enrichment analyses of SBP or DBP associated loci according to discovery *P* value using narrow peaks (panel A) or broad peaks (panel B). SNPs were selected according to different *P* value cutoffs (x-axis) and a fold enrichment of overlap with DNAse hypersensitive sites compared to unrelated GWAS SNPs was calculated (y-axis) (see **Supplementary Note**). The 12 endothelial cell-lines are indicated in color and for each endothelial cell-type the rank using the 10<sup>-14</sup> *P* value cutoff is indicated. EC denotes endothelial cells.

## 1067 TABLE LEGENDS

## 1068 **Table 1. SBP and DBP association at 66 loci.**

1069 Meta-analysis results of up to 342,415 individuals of European ancestry for SBP and DBP: Established 1070 and new loci are grouped separately. Nearest genes are shown as locus labels but this should not be 1071 interpreted as support that the causal gene is the nearest gene. The lead SNP with the lowest P value 1072 for either BP trait is shown as the lead SNP and both SBP and DBP results are presented even if both are 1073 not genome-wide significant. The SNP effects are shown according to the effect in mm Hg per copy of the coded allele (that is the allele coded 0, 1, 2) under an additive genetic model. "\*" in the lead SNP 1074 column indicates a non-synonymous coding SNP (either the SNP itself or another SNP in  $r^2$  >0.8). # 1075 1076 Established loci have smaller total sample sizes relative to novel loci (see **Supplementary Note**).

## 1077 Table 2. Overview of novel and known BP variant properties.

1078 Key characteristics of the novel and established BP loci are shown. MAF and effect size estimates are 1079 derived from the Cardio-MetaboChip data. Variance explained estimates are estimated from one large 1080 study (**Supplementary Note**). Novel loci are classified as previously unknown to be linked to BP by a 1081 systematic PubMed review of all genes in a 200kb window (**Supplementary Note**).

## 1083 Table 3. Prediction of hypertensive target organ damage by a multi-BP SNP score.

1084 Shown are the estimated effects of a BP risk score comprised of up to 66 SNPs (see column "Total 1085 #SNPs") on risk of dichotomous outcome (as odds ratios) or increment in continuous measures per predicted mmHg of the SBP or DBP score. The effect sizes are expressed as incremental change in the 1086 1087 phenotype for quantitative traits and natural logarithm of the odds ratio for binary traits, per 1 mmHg 1088 predicted increase in SBP or DBP. P values are bolded if they meet an analysis-wide significance threshold (< 0.05/18 = 0.0028). Results for all SNPs ("all") and for pruned results ("p") are shown. The 1089 1090 pruned results were obtained by iterative removal of SNPs from the risk score starting with the SNP with 1091 lowest heterogeneity P value. Iterations to remove SNPs were continued until the heterogeneity P value 1092 was < 0.0028 (see **Supplementary Note**). The number of SNPs removed when calculating the pruned 1093 results is indicated by "# SNPs rem.". The results per individual SNP can be found in Supplementary 1094 Table 15. CAD: coronary artery disease, LV: left ventricle, CKD: chronic kidney disease, eGFR: estimated 1095 glomerular filtration rate, cr: creatinine, cIMT: carotid intima: media thickness. Var. type denotes the 1096 variable type and cont. for continuous, or dic. for dichotomous. Eth. = Ethnicity, Consort. = Consortium, 1097 EUR = European ancestry, EAS = East Asian ancestry.

1099	Table 1.	New and	known	BP loci.
±033	10.010 11			D. 1000

Locus no. Locus name		Lead SNP	Chr	Position	CA	Coded	Traits	SBP				DBP			
				(hg19)	/NC	allele freq		Effect	SE	P value	Total N	Effect	SE	P value	Total N#
NEW 1	HIVEP3	rs7515635	1	42,408,070	T/C	0.468	SBP	0.307	0.0444	4.81E-12	340,969	0.1365	0.0263	2.05E-07	340,934
NEW 2	PNPT1	rs1975487	2	55,809,054	A/G	0.464	DBP	-0.2107	0.045	2.81E-06	337,522	-0.1602	0.0266	1.75E-09	337,517
NEW 3	FGD5	rs11128722	3	14,958,126	A/G	0.563	SBP & DBP	-0.3103	0.0469	3.61E-11	310,430	-0.1732	0.0279	5.16E-10	310,429
NEW 4	ADAMTS9	rs918466	3	64,710,253	A/G	0.406	DBP	-0.0865	0.0459	5.94E-02	336,671	-0.1819	0.027	1.73E-11	336,653
NEW 5	TBC1D1-FLJ13197	rs2291435	4	38,387,395	T/C	0.524	SBP & DBP	-0.3441	0.0449	1.90E-14	331,382	-0.156	0.0266	4.26E-09	331,389
NEW 6	TRIM36	rs10077885	5	114,390,121	A/C	0.501	SBP & DBP	-0.284	0.0444	1.64E-10	338,328	-0.1735	0.0263	3.99E-11	338,323
NEW 7	CSNK1G3	rs6891344	5	123,136,656	A/G	0.819	DBP	0.2811	0.058	1.24E-06	338,688	0.2311	0.0343	1.58E-11	338,678
NEW 8	CHST12-LFNG	rs2969070	7	2,512,545	A/G	0.639	SBP & DBP	-0.2975	0.0464	1.44E-10	335,991	-0.1821	0.0274	2.92E-11	335,972
NEW 9	ZC3HC1 PSMD5	rs11556924	7 9	129,663,496 123,586,737	T/C	0.384	SBP & DBP	-0.2705	0.0468 0.0457	7.64E-09 6.10E-10	325,929	-0.2141	<b>0.0276</b> 0.0269	8.15E-15	325,963
NEW 10	DBH	rs10760117 rs6271*	9	123,586,737	T/G T/C	0.415	SBP	0.283		6.10E-10 4.89E-11	333,377	0.0999 - <b>0.4646</b>		2.08E-04 <b>2.42E-18</b>	333,377
NEW 11 NEW 12	ВБП RAPSN, PSMC3, SLC39A13	rs7103648	9 11	47,461,783	A/G	0.072 0.614	SBP & DBP SBP & DBP	-0.5911 -0.3349	0.0899 0.0462	4.89E-11 4.43E-13	306,394 335,614	-0.4646	0.0532 0.0272	2.42E-18 9.03E-19	306,463 335,592
111111	NAI 3N, I 3NIC3, 32C33A13	137 103040		47,401,705			551 Q <b>55</b> 1				333,014				
NEW 13	LRRC10B	rs751984	11	61,278,246	T/C	0.879	SBP & DBP	0.4074	0.0691	3.80E-09	334,583	0.3755	0.0409	4.20E-20	334,586
NEW 14	SETBP1	rs12958173	18	42,141,977	A/C	0.306	SBP & DBP	0.3614	0.0489	1.43E-13	331,007	0.1789	0.0289	5.87E-10	331,010
NEW 15	INSR	rs4247374	19	7,252,756	T/C	0.143	SBP & DBP	-0.5933	0.0673	1.23E-18	302,458	-0.3852	0.0396	2.08E-22	302,459
NEW 16	ELAVL3	rs17638167	19	11,584,818	T/C	0.047	DBP	-0.4784	0.1066	7.13E-06	333,137	-0.3479	0.0632	3.71E-08	333,107
NEW 17	CRYAA-SIK1	rs12627651	21	44,760,603	A/G	0.288	SBP & DBP	0.3905	0.0513	2.69E-14	310,738	0.2037	0.0301	1.36E-11	310,722
EST 1	CASZ1	rs880315	1	10,796,866	T/C	0.641	SBP & DBP	-0.475	0.062	2.09E-14	184,226	-0.257	0.038	1.34E-11	184,212
EST 2	MTHFR-NPPB	rs17037390	1	11,860,843	A/G	0.155	SBP & DBP	-0.908	0.081	5.95E-29	195,493	-0.499	0.05	1.20E-23	195,481
EST 3	ST7L-CAPZA1-MOV10	rs1620668	1	113,023,980	A/G	0.822	SBP & DBP	-0.535	0.076	1.45E-12	197,966	-0.285	0.047	9.00E-10	197,948
EST 4	MDM4	rs4245739	1	204,518,842	A/C	0.737	DBP	0.326	0.068	1.37E-06 9.65E-13	191,594	0.243	0.041	4.63E-09	191,578
EST 5 EST 6	AGT KCNK3	rs2493134*	1 2	230,849,359	T/C	0.579	SBP & DBP	-0.413	0.058 0.059		199,505	-0.275	0.036 0.036	9.53E-15	199,502
EST 6 EST 7	NCAPH	rs2586886 rs772178	2	26,932,031 96,963,684	T/C A/G	0.599 0.64	SBP & DBP DBP	- <b>0.404</b> -0.072	0.059	5.94E-12 2.39E-01	<b>197,269</b> 192,513	-0.254 -0.208	0.038	1.92E-12 3.58E-08	197,272 192,501
EST 8	FIGN-GRB14	rs1371182	2	165,099,215	T/C	0.443	SBP & DBP	-0.072 -0.444	0.058	1.89E-14	196,262	-0.252	0.036	1.50E-12	192,301
EST 9	HRH1-ATG7	rs2594992	3	11,360,997	A/C	0.607	SBP	-0.334	0.06	2.31E-08	189,895	-0.136	0.037	2.20E-04	189,854
EST 10	SLC4A7	rs711737	3	27,543,655	A/C	0.604	SBP	0.334	0.058	9.93E-09	200,282	0.130	0.036	2.24E-06	200,260
EST 11	ULK4	rs2272007*	3	41,996,136	T/C	0.18	DBP	-0.11	0.077	1.52E-01	193,915	0.328	0.047	3.94E-12	193,900
EST 12	MAP4	rs6442101*	3	48,130,893	T/C	0.692	SBP & DBP	0.396	0.062	1.62E-10	200,543	0.303	0.038	1.60E-15	200,534
EST 13	МЕСОМ	rs6779380	3	169,111,915	T/C	0.539	SBP & DBP	-0.439	0.06	1.85E-13	186,535	-0.239	0.037	6.87E-11	186,521
EST 14	FGF5	rs1458038	4	81,164,723	T/C	0.3	SBP & DBP	0.659	0.065	5.36E-24	188,136	0.392	0.04	7.36E-23	188,088
EST 15	ARHGAP24	rs17010957	4	86,719,165	T/C	0.857	SBP	-0.498	0.082	1.51E-09	196,325	-0.173	0.051	6.63E-04	196,292
EST 16	SLC39A8	rs13107325	4	103,188,709	T/C	0.07	SBP & DBP	-0.837	0.127	4.69E-11	175,292	-0.602	0.078	1.63E-14	175,372
EST 17	GUCY1A3-GUCY1B3	rs4691707	4	156,441,314	A/G	0.652	SBP	-0.349	0.06	7.10E-09	198,246	-0.163	0.037	1.08E-05	198,226
EST 18	NPR3-C5orf23	rs12656497	5	32,831,939	T/C	0.403	SBP & DBP	-0.487	0.06	3.85E-16	194,831	-0.228	0.037	4.73E-10	194,829
EST 19	EBF1	rs11953630	5	157,845,402	T/C	0.366	SBP & DBP	-0.38	0.065	3.91E-09	167,698	-0.23	0.04	8.07E-09	167,708
EST 20	HFE	rs1799945*	6	26,091,179	C/G	0.857	SBP & DBP	-0.598	0.086	3.28E-12	185,306	-0.43	0.053	3.10E-16	185,273
EST 21	BAT2-BAT5	rs2187668	6	32,605,884	T/C	0.126	DBP	-0.291	0.092	1.60E-03	189,806	-0.372	0.057	4.31E-11	189,810
EST 22	ZNF318-ABCC10	rs6919440	6	43,352,898	A/G	0.57	SBP	-0.337	0.058	4.92E-09	200,733	-0.125	0.035	4.25E-04	200,730
EST 23	RSPO3	rs1361831	6	127,181,089	T/C	0.541	SBP & DBP	-0.482	0.058	7.38E-17	197,027	-0.271	0.036	2.34E-14	197,012
EST 24	PLEKHG1	rs17080093	6	150,997,440	T/C	0.075	DBP	-0.564	0.111	3.83E-07	194,728	-0.411	0.068	1.71E-09	194,734
EST 25	HOTTIP-EVX	rs3735533	7	27,245,893	T/C	0.081	SBP & DBP	-0.798	0.106	6.48E-14	197,881	-0.445	0.065	1.09E-11	197,880
EST 26	PIK3CG	rs12705390	7	106,410,777	A/G	0.227	SBP	0.619	0.069	2.69E-19	198,297	0.059	0.042	1.63E-01	198,290
EST 27	BLK-GATA4	rs2898290	8	11,433,909	T/C	0.491	SBP	0.377	0.058	8.85E-11	197,759	0.167	0.036	3.17E-06	197,726
EST 28	CACNB2	rs12243859	10	18,740,632	T/C	0.326	SBP & DBP	-0.402	0.061	6.13E-11	199,136	-0.335	0.038	8.11E-19	199,124
EST 29	C10orf107	rs7076398	10	63,533,663	A/T	0.188	SBP & DBP	-0.563	0.076	1.72E-13	187,013	-0.409	0.047	2.55E-18	187,024
EST 30	SYNPO2L	rs12247028	10	75,410,052	A/G	0.611	SBP	-0.364	0.063	8.16E-09	180,194	-0.159	0.039	3.89E-05	180,094
EST 31	PLCE1	rs932764*	10	95,895,940	A/G T/C	0.554	SBP & DBP	-0.495	0.059	6.88E-17	195,577	-0.224	0.036	6.28E-10	195,547
EST 32	CYP17A1-NT5C2	rs943037	10	104,835,919		0.087	SBP & DBP	-1.133	0.105	2.35E-27	193,818	-0.482	0.064	4.48E-14	193,799
EST 33 EST 34	ADRB1 LSP1-TNNT3	rs740746 rs592373	10 11	115,792,787 1,890,990	A/G A/G	0.73 0.64	SBP & DBP SBP & DBP	0.486 0.484	0.067 0.063	4.59E-13 2.02E-14	184,835 177,149	0.32 0.282	0.041 0.039	8.63E-15 3.61E-13	184,868 177,134
EST 34	ADM	rs1450271	11	10,356,115	T/C	0.468	SBP & DBP	0.484	0.059	3.40E-12	191,246	0.282	0.039	4.11E-08	191,221
EST 36	PLEKHA7	rs1156725	11	16,307,700	T/C	0.408	SBP & DBP	-0.447	0.072	5.65E-12	200,889	-0.292	0.044	3.67E-11	200,899
EST 36 EST 37	SIPA1	rs1156725 rs3741378*	11	65,408,937	T/C	0.804	SBP & DBP	-0.447	0.072	8.04E-09	194,563	-0.183	0.044	4.17E-04	194,551
EST 38	FLJ32810-TMEM133	rs633185	11	100,593,538	C/G	0.715	SBP & DBP	0.522	0.067	6.97E-15	183,845	0.288	0.041	2.38E-12	183,825
EST 38	PD52810-TWEWI55 PDE3A	rs3752728	12	20,192,972	A/G	0.713	DBP	0.322	0.066	4.32E-07	200,440	0.288	0.041	2.38E-12 2.35E-15	200,408
EST 40	ATP2B1	rs11105354	12	90,026,523	A/G	0.84	SBP & DBP	0.909	0.081	3.88E-29	195,206	0.459	0.05	2.61E-20	195,195
EST 41	SH2B3	rs3184504*	12	111,884,608	T/C	0.475	SBP & DBP	0.498	0.062	9.97E-16	177,067	0.362	0.038	1.28E-21	177,122
EST 42	TBX5-TBX3	rs2891546	12	115,552,499	A/G	0.11	DBP	-0.529	0.1	1.36E-07	172,012	-0.38	0.061	4.71E-10	171,980
EST 43	CYP1A1-ULK3	rs936226	15	75,069,282	T/C	0.722	SBP & DBP	-0.549	0.067	3.06E-16	187,238	-0.363	0.041	1.03E-18	187,221
EST 44	FURIN-FES	rs2521501	15	91,437,388	A/T	0.684	SBP & DBP	-0.639	0.069	3.35E-20	164,272	-0.358	0.042	1.85E-17	164,255
EST 45	PLCD3	rs7213273	17	43,155,914	A/G	0.658	SBP	-0.413	0.066	4.71E-10	164,795	-0.185	0.041	7.23E-06	164,788
EST 46	GOSR2	rs17608766	17	45,013,271	T/C	0.854	SBP	-0.658	0.083	2.27E-15	188,895	-0.218	0.051	1.95E-05	188,928
EST 47	ZNF652	rs12940887	17	47,402,807	T/C	0.38	DBP	0.321	0.06	7.06E-08	192,546	0.261	0.037	1.07E-12	192,524
EST 48	JAG1	rs1327235	20	10,969,030	A/G	0.542	SBP & DBP	-0.395	0.059	2.23E-11	192,680	-0.308	0.036	1.78E-17	192,659
EST 49	GNAS-EDN3	rs6026748	20	57,745,815	A/G	0.125	SBP & DBP	0.867	0.089	3.15E-22	192,338	0.552	0.055	4.86E-24	192,327

## Table 2. Overview of novel and known BP variant properties.

	17 new loci	49 established loci	66 loci
Minor allele frequency (mean, range)	32.1% [5%-50%]	28.9% [7%-49%]	29.8% [5%-50%]
Effect size SBP [mmHg] (range, mean)	0.09-0.59, 0.34	0.07-1.13, 0.5	0.07-1.13, 0.46
Effect size DBP [mmHg] (range, mean)	0.1-0.46, 0.23	0.06-0.60, 0.3	0.06-0.6, 0.28
Variance explained SBP Variance explained DBP	0.52% 0.58%	2.95% 2.78%	3.46% 3.36%

Table 3. BF	P risk score	effects on	disease	outcomes.
-------------	--------------	------------	---------	-----------

Phenotype	Var. type (cont./	Eth.	Consort.	Total N or no. ca/co	Total #SNPs			SBP_score					DBP_score		
	dic.)			,		effect (all)	P value (all)	het. <i>P</i> value (all)	<i>P</i> value (p)	# SNPs rem.	effect (all)	P value (all)	het. <i>P</i> value (all)	<i>P</i> value (p)	# SNPs rem.
HEART															
CAD	dich.	EUR SAS	CARDIoG RAMplus C4D	63,746 /130,681	61	1.042	1.72E-44	1.75E-25	4.08E-32	10	1.069	1.19E-42	6.63E-27	2.2E-38	10
heart failure	dich.	EUR	CHARGE	2,526 /18,400	66	1.021	2.77E-02	1.63E-01	2.77E-02	0	1.035	2.31E-02	1.70E-01	2.31E-02	0
LV mass	cont.	EUR	CHARGE	11,273	66	0.480	6.43E-04	3.58E-01	6.43E-04	0	0.754	1.23E-03	3.21E-01	1.23E-03	0
LV wall thickness	cont.	EUR	CHARGE	11,311	66	0.004	4.45E-06	5.83E-02	4.45E-06	0	0.007	3.19E-06	6.40E-02	3.19E-06	0
KIDNEY															
CKD	dich.	EUR	CHARGE	6,271 /68,083	65	1.010	1.37E-01	1.77E-03	2.65E-01	1	1.008	4.49E-01	1.25E-03	7.69E-01	1
eGFR (based on cr)	cont.	EUR	CHARGE	74,354	65	0.000	7.07E-01	3.12E-05	3.22E-01	2	0.000	9.41E-01	3.02E-05	9.65E-01	2
eGFR (based on cystatin)	cont.	EUR	CHARGE	74,354	65	0.001	9.05E-02	9.28E-06	4.11E-01	1	0.001	3.30E-01	5.64E-06	6.9E-01	1
creatinine	cont.	EUR	KidneyGE N	23,812	66	0.000	9.42E-01	6.31E-03	9.42E-01	0	0.000	4.11E-01	7.16E-03	4.11E-01	0
microalbuminuria	dich.	EUR	CHARGE	2,499 /29,081	65	0.011	2.10E-01	4.79E-02	2.1E-01	0	0.023	1.02E-01	5.66E-02	1.02E-02	0
urinary albumin/cr ratio	cont.	EUR	CHARGE	31,580	65	0.009	2.52E-03	3.02E-04	0.53E-03	1	0.015	2.40E-03	3.08E-04	8.31E-03	1
STROKE															
stroke, all subtypes	dich.	EUR	CHARGE	1,544 /18,058	66	0.056	6.11E-06	8.26E-02	6.11E-06	0	0.085	3.79E-05	4.98E-02	3.79E-05	0
stroke, ischemic subtype	dich.	EUR	CHARGE	1,164 /18,438	66	0.067	3.33E-06	1.75E-01	3.33E-06	0	0.096	5.63E-05	8.82E-02	5.63E-05	0
stroke, ischemic subtype	dich.	EUR	MetaStro ke	11,012 /40,824	66	0.036	1.69E-10	4.72E-02	1.69E-10	0	0.056	1.29E-09	2.51E-02	1.29E-09	0
VASCULATURE															
cIMT	cont.	EUR	CHARGE	27,610	66	0.004	4.80E-15	5.06E-08	7.32E-10	4	0.005	4.15E-11	3.84E-10	6.2E-07	5
EYE															
mild retinop.	dich.	EUR	CHARGE	1,122 /18,289	66	1.021	1.37E-01	6.01E-03	1.37E-01	0	1.046	5.78E-02	7.81E-03	5.78E-02	0
central retinal artery caliber	cont.	EUR	CHARGE	18,576	66	0.343	3.29E-14	2.56E-06	2.06E-13	2	0.570	3.61E-14	2.44E-06	7.05E-13	3
mild retinop.	dich.	EAS	SEED	289 /5,419	66	1.033	2.55E-01	2.42E-01	2.55E-01	0	1.087	8.55E-02	2.87E-01	8.55E-02	0
central retinal artery caliber	cont.	EAS	SEED	6,976	63	0.320	1.39E-04	9.07E-01	1.39E-04	0	0.533	2.19E-04	8.91E-01	2.19E-04	0

## **ONLINE METHODS**

## Cohorts contributing to systolic (SBP) and diastolic blood pressure (DBP) analyses

Studies contributing to BP association discovery including community- and population-based collections as well as studies of non-BP traits, analyzed as case and control samples separately. Details on each of the studies including study design and BP measurement are provided in **Supplementary Table 1**, genotyping information in **Supplementary Table 2**, and participant characteristics in **Supplementary Table 3**. All participants provided written informed consent and the studies were approved by local Research Ethics Committees and/or Institutional Review Boards.

## European ancestry meta-analysis

BP was measured using standardized protocols in all studies regardless of whether the primary focus was BP or another trait. We initially analyzed affected and unaffected individuals from samples selected as cases (e.g. type 2 diabetes) or controls, separately. However, because sensitivity analyses did not reveal any significant difference in BP effect size estimates between case and control samples (data not shown), we analyzed all samples combined. When available, the average of two BP measurements was used for association analyses (**Supplementary Table 1**). If an individual was taking a BP-lowering treatment, the underlying systolic BP (SBP) and diastolic BP (DBP) were estimated by adding 15 mmHg and 10 mmHg, respectively, to the measured values, as done in prior analyses.

A meta-analysis of 340,934 individuals of European descent was undertaken in four stages with subsequent validation in an independent cohort. Because stage 1 Cardio-MetaboChip samples included many SNPs selected on the basis of association with BP in earlier GWAS, we performed genomic control using a set of putative null SNPs based on P > 0.10 in earlier GWAS of SBP and DBP or both. Stage 2 samples with genome-wide genotyping used the entire genome-wide set of SNPs for genomic control given the lack of ascertainment. The study design is summarized in **Supplementary Figure 1**, and further details are provided in **Supplementary Tables 2-5** and the **Supplementary Note**.

## Systematic PubMed search +/- 100kb of each newly discovered index SNP

All genes with any overlap with a 200kb region centered around each of the 17 newly discovered lead SNPs were identified using the UCSC Genome Browser. A search term was constructed for each gene including the short and long gene name and the terms "blood pressure" and "hypertension" (e.g. for *NPPA* on chr 1: "NPPA OR natriuretic peptide A AND (blood pressure OR hypertension)") and the search results of each search term from PubMed were individually reviewed.

## Trait variance explained

The trait variance explained by 66 lead SNPs at novel and known loci was evaluated in one study that contributed to the discovery effort: the Atherosclerosis Risk in Communities (ARIC) study. We constructed a linear regression model with all 66 or the subset of 49 known SNPs as a set of predictors of the BP residual after adjustment for covariates of the adjusted treatment-corrected BP phenotype (SBP or DBP). The r<sup>2</sup> from the regression model was used as the estimate of trait variance explained.

## European ancestry GCTA-COJO analysis

To identify multiple distinct association signals at any given BP locus, we undertook approximate conditional analyses using a model selection procedure implemented in the GCTA-COJO software package<sup>44,45</sup>. To evaluate the robustness of the GCTA-COJO results to the choice of reference data set, model selection was performed using the LD between variants in separate analyses from two datasets of European descent, both with individuals from the UK with Cardio-MetaboChip genotype data: GoDARTS with 7,006 individuals and WTCCC1-T2D/58BC with 2,947 individuals. Assuming that the LD between

SNPs more than 10 Mb away or on different chromosomes is zero, we undertook the GCTA-COJO stepwise model selection to select SNPs that were conditionally-independently associated with SBP and DBP, in turn, at a genome-wide significance, given by  $P < 5 \times 10^{-8}$  (**Supplementary Tables 6-8**) using the stage 4 combined European GWAS+ Cardio-MetaboChip meta-analysis.

## Conditional analyses in the Women's Genome Health Study (WGHS)

Multivariable regression modeling was performed for each possible combination of putative independent SNPs from a) model selection implemented in GCTA-COJO and b) a comprehensive manual review of the literature (**Supplementary Table 9**). Any SNP with  $P < 5 \times 10^{-8}$  in a previous reported BP GWAS was considered. A total of 46 SNPs were examined (**Supplementary Table 10**). Genome-wide genotyping data imputed to 1000 Genomes in the WGHS (N = 23,047) were used. Regression modeling was performed in the R statistical language (**Supplementary Table 10**).

## Fine mapping and determination of credible sets of causal SNPs

The GCTA-COJO and WGHS conditional analyses identified multiple distinct signals of association at multiple loci (**Supplementary Tables 6 and 10**). Of the 24 loci considered in fine-mapping analyses, 16 had no evidence for the existence of multiple distinct association signals, so it is reasonable to assume that there is a single causal SNP and therefore the credible sets of variants could be constructed using the association summary statistics from the unconditional meta-analyses. However, in the remaining eight loci, where evidence of secondary signals was observed from GCTA-COJO, we performed approximate conditional analyses across the region by conditioning on each index SNP (**Supplementary Table 11**). By adjusting for the other index SNPs at the locus, we can therefore assume a single variant is driving each "conditionally-independent" association signal, and we can construct the 99% credible set of variants on the basis of the approximate conditional analysis from GCTA-COJO (**Supplementary Tables 12-13**). At five of the eight loci with multiple distinct signals of association, one index SNP mapped outside of the fine-mapping region, so a credible set could not be constructed.

## eQTL analysis: Whole Blood

NESDA/NTR: Whole blood eQTL analyses were performed in samples from the Netherlands Study of Depression and Anxiety (NESDA)<sup>46</sup> and the Netherlands Twin Registry (NTR)<sup>47</sup> studies. RNA expression analysis was performed in the statistical software R. The residuals resulting from the linear regression analysis of the probe set intensity values onto the covariates sex, age, body mass index (kg/m<sup>2</sup>), smoking status coded as a categorical covariate, several technical covariates, and three principal components were used. The eQTL effects were detected using a linear mixed model approach, including for each probe set the expression level (normalized, residualized and without the first 50 expression PCs) as dependent variable; the SNP genotype values as fixed effects; and family identifier and zygosity (in the case of twins) as random effects to account for family and twin relations<sup>48</sup>.

The eQTL effects were defined as *cis* when probe set–SNP pairs were at distance < 1M base pairs. At a FDR of 0.01 applied genome-wide, not just for candidate SNPs, the *P* value threshold was  $1 \times 10^{-4}$  for the *cis*-eQTL analysis. For each probe set that displayed a statistically significant association with at least one SNP located within its *cis* region, we identified the most significantly associated SNP and denoted this as the top *cis*-eQTL SNP. See **Supplementary Note** for details.

## eQTL analysis: Selected published eQTL datasets

Lead BP SNP and proxies ( $r^2 > 0.8$ ) were searched against a collected database of expression SNP (eSNP) results. The reported eSNP results met criteria for statistical thresholds for association with gene transcript levels as described in the original papers. The non-blood cell tissue eQTLs searched included

aortic endothelial cells<sup>49</sup>, left ventricle of the heart <sup>50</sup>, cd14+ monocytes <sup>51</sup> and the brain <sup>52</sup>. The results are presented in **Supplementary Tables 14-15**.

## Enrichment analyses: Analysis of cell-specific DNase hypersensitivity sites (DHSs) using an OR method

The overlap of Cardio-MetaboChip SNPs with DHSs was examined using publicly available data from the Epigenomics Roadmap Project and ENCODE, choosing different cutoffs of Cardio-MetaboChip *P* values. The DHS mappings were available for 123 mostly adult cells and tissues <sup>53</sup> (downloaded from The DHS mappings were specified as both "narrow" and "broad" peaks, referring to reduction of the experimental data to peak calls at 0.1% and 1.0% FDR thresholds, respectively. Thus, the "narrow" peaks are largely nested within the "broad" peaks. Experimental replicates of the DHS mappings (typically duplicates) were also available for the majority of cells and tissues.

SNPs from the Cardio-MetaboChip genome-wide scan were first clumped in PLINK in windows of 100kb and maximum  $r^2 = 0.1$  among LD relationships from the 1000 Genomes European data. Then, the resulting index SNPs at each *P* value threshold were tagged with  $r^2 = 0.8$  in windows of 100kb, again using LD relationships in the 1000 Genomes, restricted to SNPs with MAF > 1% and also present in the HapMap2 CEU population. A reference set of SNPs was constructed using the same clumping and tagging procedures applied to GWAS catalog SNPs (available at http://www.genome.gov/gwastudies/, accessed 3/13/2013)<sup>54</sup> with discovery *P* <  $5x10^{-8}$  in European populations. A small number of reference SNPs or their proxies overlapping the BP SNPs or their proxies were excluded. After LD pruning and exclusions, there were a total of 1,196 reference SNPs. For each cell type and *P* value threshold, the enrichment of SBP or DBP SNPs (or their LD proxies) mapping to DHSs was expressed as an odds ratio (OR) relative to the GWAS catalog reference SNPs (or their LD proxies), using logistic mixed effect models treating the replicate peak determinations as random effects (glmer package in R). The significance of the enrichment ORs was derived from the significance of beta coefficients for the main effects in the mixed models (**Figure 2, Supplementary Table 16**).

## Enrichment analyses: Analysis of tissue-specific enrichment of BP variants and H3K4me3 sites

An analysis to test for significant cell-specific enrichment in the overlap of BP SNPs (or their proxies) with H3K4me3 sites was performed as described in Trynka et al, 2013<sup>55</sup>. The measure of overlap is a "score" that is constructed by dividing the height of an H3K4me3 ChIP signal in a particular cell by the distance between the nearest test SNP. The significance of the scores (i.e. *P* value) for all SNPs was determined by a permutation approach that compares the observed scores to scores of SNPs with similar properties to the test SNPs, essentially in terms of LD and proximity to genes (**Supplementary Note**). The number of permutations determined the number of significant digits in the *P* values and we conducted 10,000 iterations. Results are shown in **Supplementary Table 19**.

## Enrichment analyses: Analysis of tissue-specific DHSs and chromatin states using GREGOR

The DNase-seq ENCODE data for all available cell types were downloaded in the processed "narrowPeak" format. The local maxima of the tag density in broad, variable-sized "hotspot" regions of chromatin accessibility were thresholded at FDR 1% with peaks set to a fixed width of 150bp. Individual cell types were further grouped into 41 broad tissue categories by taking the union of DHSs for all related cell types and replicates. For each GWAS locus, a set of matched control SNPs was selected based on three criteria: 1) number of variants in LD ( $r^2 > 0.7$ ; ± 8 variants), 2) MAF (± 1%), and 3) distance to nearest gene (± 11,655 bp). To calculate the distance to the nearest gene, the distance to the 5' flanking gene (start and end position) and to the 3' flanking gene was calculated and the minimum of these 4 values was used. If the SNP fell within the transcribed region of a gene, the distance was 0. The probability that a set of GWAS loci overlap with a regulatory feature more often than we expect by chance was estimated.

## Enrichment analyses: FAIRE analysis of BP variants in fine-mapping regions in lymphoblastoid cell lines

FAIRE analysis was performed on a sample of 20 lymphoblastoid cell lines of European origin. All samples were genotyped using the Cardio-MetaboChip genotyping array, and BP SNPs and LD proxies ( $r^2 > 0.8$ ) at the fine mapping loci (N = 24, see **Supplementary Table 23**) were assessed to identify heterozygous imbalance between non-treated and FAIRE-treated chromatin. A paired t-test was used to compare the B allele frequency (BAF) arising from formaldehyde-fixed chromatin sheared by sonication and DNA purified to the BAF when the same chromatin sample underwent FAIRE to enrich for open chromatin. Three hundred and fifty-seven Cardio-MetaboChip BP SNPs were directly genotyped across the fine mapping regions. The Bonferroni-corrected threshold of significance is P < 0.0001 (0.05/357). The results for SNPs with P < 0.05 are reported in (**Supplementary Table 23**). FAIRE results were not available for some SNPs with missing data due to genotype failure or not having >3 heterozygous individuals for statistical analysis. Therefore there are no results for three lower frequency BP loci (*SLC39A8, CYP17A1-NT5C2* and *GNAS-EDN3*) and for the second signal at the following loci: *MTHFR-NPPB* (rs2272803), *MECOM* (rs2242338) and *HFE* rs1800562).

## Pathway analyses: MAGENTA

MAGENTA tests for enrichment of gene sets from a precompiled library derived from GO, KEGG, PATHTER, REACTOME, INGENUITY, and BIOCARTA was performed as described by Segré et al,  $2010^{56}$ . Enrichment of significant gene-wide *P* values in gene sets is assessed by 1) using LD and distance criteria to define the span of each gene, 2) selecting the smallest *P* value among SNPs mapping to the gene span, and 3) adjusting this *P* value using a regression method that accounts for the number of SNPs, the LD, etc. In the second step, MAGENTA examines the distribution of these adjusted *P* values and defines thresholds for the 75%ile and the 95%ile. In the third step, MAGENTA calculates an enrichment for each gene set by comparing the number of genes in the gene set with *P* value less than either the 75th or 95th %ile to the number of genes in the gene set with *P* value greater than either the 75th or 95th %ile, and then comparing this quotient to the same quotient among genes not in the gene set. This gene-set quotient is assigned a *P* value based on reference to a hypergeometric distribution. The results based on our analyses are indicated in **Supplementary Table 21**.

## Pathway analyses: DEPICT

We applied the DEPICT <sup>57</sup> analysis separately on genome-wide significant loci from the overall blood pressure (BP) Cardio-MetaboChip analysis including published blood pressure loci (see **Supplementary Table 22**). SNPs at the *HFE* and *BAT2-BAT5* loci (rs1799945, rs1800562, rs2187668, rs805303, rs9268977) could not be mapped. As a secondary analysis, we additionally included associated loci ( $P < 1x10^{-5}$ ) from the Cardio-MetaboChip stage 4 combined meta-analyses of SBP and the DBP. DEPICT assigned genes to associated regions if they overlapped or resided within associated LD blocks with r<sup>2</sup> > 0.5 to a given associated SNP.

## Literature review for genes at the newly discovered loci

Recognizing that the most significantly associated SNP at a locus may not be located in the causal gene and that the functional consequences of a SNP often extends beyond 100kb, we conducted a literature review of genes in extended regions around newly discovered BP index SNPs. The genes for this extensive review were identified by DEPICT (**Supplementary Table 22**).

## Non-European meta-analysis

To assess the association of the 66 significant loci from the European ancestry meta-analysis in non-European ethnicities, we obtained lookup results for the 66 index SNPs for participants of South-Asian ancestry (8 datasets, total N = 20,875), East-Asian ancestry (5 datasets, total N = 9,637), and African- and African-American ancestry (6 datasets, total N = 33,909). The association analyses were all conducted with the same covariates (age, age<sup>2</sup>, sex, BMI) and treatment correction (+15/10 mm Hg in the presence of any hypertensive medication) as the association analyses for the discovery effort in Europeans. Tests for heterogeneity across effect estimates in European, South Asian, East Asian and African derived samples were performed using GWAMA<sup>58</sup>.

## Genetic risk score and cardiovascular outcomes

The gtx package for the R statistical programming language was used to estimate the effect of the SNP-risk score on the response variable in a regression model<sup>59</sup>.

## METHODS ONLY REFERENCES

- 44. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88, 76-82 (2011).
- 45. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 44, 369-75, S1-3 (2012).
- 46. Penninx, B.W. et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 17, 121-40 (2008).
- 47. Boomsma, D.I. et al. Netherlands Twin Register: from twins to twin families. Twin Res Hum Genet 9, 849-57 (2006).
- 48. Visscher, P.M., Benyamin, B. & White, I. The use of linear mixed models to estimate variance components from data on twin pairs by maximum likelihood. Twin Res 7, 670-4 (2004).
- 49. Romanoski, C.E. et al. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. Circ Res 109, e27-41 (2011).
- 50. Koopmann, T.T. et al. Genome-wide identification of expression quantitative trait loci (eQTLs) in human heart. PLoS One 9, e97380 (2014).
- 51. Fairfax, B.P. et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 343, 1246949 (2014).
- 52. Ramasamy, A. et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci 17, 1418-28 (2014).
- 53. Maurano, M.T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190-5 (2012).
- 54. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42, D1001-6 (2014).
- 55. Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 45, 124-30 (2013).
- 56. Segre, A.V. et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 6(2010).
- 57. Pers, T.H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat Commun 6, 5890 (2015).
- 58. Magi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 11, 288 (2010).

59. Johnson, T. Efficient Calculation for Multi-SNP Genetic Risk Scores. ASHG 2012 Annual Meeting, poster presentation.

# 

# 


5C2, AD PLEKHA 9A13, LF PSMD5, DBH CACNB2 CACNB2 C10orf107, SYNPO2L PLCE1, CYP17A1-NT5 LSP1-TNNT3, ADM, PI LSP1-TNNT3, ADM, PI RAPSN PSMC3 SLC39 FLJ32810-TMEM133 FLJ32810-TMEM133 FLJ32810-TMEM133 FLJ3281, SH2B3 TBX5-TBX3

ČCYP1A1-ULK3, FURIN-FES PLCD3, GOSR2, ZNF652 PLCD3, GOSR2, ZNF652 SETBP1 SETBP1 INSR, ELAVL3 INSR, ELAVL3 INSR, ELAVL3 INSR, ELAVL3 INSR, ELAVL3 CRYAA-SIK1 CRYAA-SIK1

new established p-value lower than 10^-15


SBP





## $\mathbf{O}$ $\mathcal{O}$ $\mathbf{O}$ **L** $\mathbf{O}$

Genomic position by chromosome



4

U

0


Caszt, MTHFR-NPPB HIVEP3 ST7L-CAPZA1-MOV10 ST7L-CAPZA1-MOV10 ST7L-CAPZA1-MOV10 MDM4 intergenic\_ch2mb6, KCNK3 MDM4 FIGN-GRB14 FIGN-GR

SYP1A1-ULK3, FUF SYP1A1-ULK3, FUF CCD3, GOSR2, ZN CCD3, GOSR2, ZN SETBP1 STBP1 STBP1 STBP1 STBP1 STBP1 STBP1 STBP1 STAA-SIK1


new established × p-value lower than 10^-15








## A) Narrow DHS region definition





# **B) Broad DHS region definition**

- #17: brain MEC

